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ABSTRACT 
 
Aeromonas hydrophila uses the type II secretion system to transport protein toxins 
across the outer membrane. The trans-envelope system is comprised of more than ten 
proteins, including ExeA and ExeB, which form a complex in the inner membrane and are 
required for assembly of the ExeD secretion channel multimer, called the secretin, into the 
outer membrane. A putative peptidoglycan binding domain (Pfam protein families database 
number PF01471) is present in the periplasmic region of ExeA (pExeA), leading to the 
hypothesis that ExeA generates gaps in peptidoglycan, a barrier for trans-envelope transport 
and apparatus assembly, to allow ExeD to assemble into the outer membrane. 
In this study, interactions between ExeA and peptidoglycan were examined both in vivo 
and in vitro. Wild type ExeA, but not the mutants containing substitution mutations of three 
highly conserved amino acid residues in the putative peptidoglycan binding domain, was 
cross-linked to peptidoglycan in vivo with DTSSP. Furthermore, the presence of wild type 
ExeA was also required for co-crosslinking of ExeB and ExeC to peptidoglycan. In vitro 
cosedimentation revealed that purified pExeA was able to bind to highly purified 
peptidoglycan. The protein assembled into large multimers in the presence of peptidoglycan 
fragments, as shown in cross-linking and co-gel filtration experiments. The requirement of 
peptidoglycan for multimerization was abrogated when the protein was incubated at 
temperatures above 25 °C. Two pExeA constructs, which disrupted the putative 
peptidoglycan binding domain, greatly reduced the cosedimentation, accompanied by 
decreased multimerization in the presence of peptidoglycan fragments. These results provide 
evidence that the putative peptidoglycan binding domain of ExeA is involved in physical 
contact with peptidoglycan. The interactions cause ExeA to multimerize, possibly forming a 
ring-like structure on the peptidoglycan, to generate a gap large enough to accommodate the 
secretion apparatus and/or to form an assembly scaffold.  
The putative peptidoglycan binding domain of ExeA was also analyzed by comparing 
its amino acid sequence with that of other homologues. The highly conserved amino acid 
residues were found to cluster at one pocket on the surface in the crystal structure of 
hydrolase metallo (Zn) DD-peptidase that also contains this domain. We propose that this 
pocket is the binding site for the peptidoglycan ligand. 
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1. INTRODUCTION 
1.1 Protein toxin secretion systems in Gram-negative bacteria 
Bacteria are enclosed by membrane barriers to preserve the integrity of the cells. 
However, the barriers must be somehow made selectively permeable to allow certain 
molecules to travel into and out of the cells, for example for the acquisition of nutrients, the 
secretion of extracellular enzymes and toxins and the assembly of trans-envelope organelles 
such as pili and flagella (Holland, 2004). Bacteria have developed many trans-membrane 
machineries for translocation of specific molecules across the inner (cytoplasmic) membrane, 
the outer membrane, or both. The Sec pathway, which recognizes the N-terminal signal 
sequence of polypeptides, is the major route for transport of unfolded proteins into and 
across the cytoplasmic membrane and is evolutionary conserved in all kingdoms of life 
(Veenendaal et al., 2004). Recently, twin-arginine translocation (Tat) system, which 
recognizes an N-terminal signal sequence containing a twin-arginine consensus motif, was 
identified (Natale et al., 2008). The most remarkable feature of the Tat system is that it is 
able to transport folded proteins across the cytoplasmic membrane. In Gram-positive 
bacteria, protein secretion is generally carried out by the Sec and Tat systems across the 
cytoplasmic membrane, although a multicomponent system, called the Type VII secretion 
system, has been identified recently in a few Gram-postitive bacteria (van Wely et al., 2001; 
Abdallah et al., 2007). In addition, Gram-negative bacteria have developed several pathways 
to deliver extracellular proteins across the outer membrane into the external medium or 
directly into their target cells. Six secretion systems, from type I to type VI (T1SS to T6SS), 
have been identified to date and will be summarized briefly in the following sections. The 
T2SS is the subject of this thesis and will be addressed in detail in section 1.2. 
 
1.1.1 Type I secretion system 
The T1SS transports unfold proteins from the cytoplasm to extracellular medium in a 
single step, independent of the Sec pathway. The apparatus forms a trans-envelope structure, 
including an inner membrane ABC (ATP-binding cassette) protein, a channel-forming outer 
membrane protein (OMP) and a membrane fusion protein (MFP) which connects the above 
two proteins (Buchanan, 2001), as illustrated in Fig. 1. The ABC protein belongs to a large 
family of ABC transporters, which are involved in transport of a diverse range of substrates
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Fig. 1 Model of the T1SS system. The T1SS apparatus is comprised of an inner membrane 
protein ABC, an outer membrane protein OMP and a membrane fusion protein MFP. The 
secretion signal is located at the C-terminus of unfolded secreted protein. CM: cytoplasmic 
(inner) membrane. OM: outer membrane. The figure is modified from Delepelaire (2004). 
 
 
 
 
 
2 
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into and out of the cell, for example, uptake of nutrients, secretion of toxins and efflux of 
antibiotics. ATP hydrolysis by this protein is required to provide energy for transport of these 
molecules against a concentration gradient. OMP forms a long trimeric channel, including a 
β-barrel in the outer membrane and an α-helical hovel extending into the periplasmic space, 
as illustrated by the crystal structure of TolC (Koronakis et al., 2000). The assembly of the 
three-protein apparatus is proposed to be triggered by binding of the protein substrate to the 
ABC protein and consequent interactions between the ABC, MFP and OMP (Delepelaire, 
2004). The secretion signal of the protein substrate is located at the C-terminal end and tends 
to form an α-helical structure. Three possible signals have been identified, including: (1), an 
essential amphiphilic α-helix followed by a nonessential α-helix and an unstructured C-
terminal domain favouring non-positively charged residues; (2), a negatively charged residue 
followed by three hydrophobic residues; and (3), glycin-rich repeats (Delepelaire, 2004). 
The glycin-rich repeats (GGXGXDXXX) are very remarkable in that the residues G2, G4 
and D6 in one repeat and G1, X3 and D6 in another come together in a β-roll structure to 
bind a Ca2+ ion (Baumann et al., 1993).   
 
1.1.2 Type III secretion system 
The T3SS features a trans-envelope needle-like structure that is able to deliver bacterial 
protein effectors to the extracellular medium or directly into host cells (He et al., 2004), as 
illustrated in Fig. 2. About 20 genes encoding T3SS components are usually found in large 
pathogenicity islands that often have different G+C composition compared to the rest of the 
chromosome, suggesting that they are acquired by horizontal transfer (Hacker and Kaper, 
2000). The T3SS needle-like structure shares striking similarities with flagella in core 
protein component sequences, assembly, secretion mechanism and morphology. Some 
reports even show that the two systems can secrete the same proteins under certain 
conditions (Young and Young, 2002; Lee and Galán, 2004). It has been proposed that the 
T3SS is evolved from an ancient flagella assembly system, or the virulence-associated T3SS 
and flagella both belong to the T3SS families evolved from a common ancestor (Gophna et 
al., 2003). One of the differences between the two systems is that the T3SS apparatus 
contains an outer membrane multimer, called secretin, which is also conserved in T2SS, type 
IV pilus and filamentous phage secretion but not in flagella (c.f. secretin in section 1.2).
  
 
                          
Fig. 2 Model of the T3SS system in plant pathogenic bacteria. The needle-like T3SS 
apparatus is comprised of about 20 proteins, ressembling the structure of flagellum. In plant 
pathogen Pseudomonas syringae, the T3SS is encoded by a cluster of hypersensitive 
response and pathogenicity (hrp) genes that are required to trigger hypersensitive response (a 
plant defense response) or to cause disease in plants. The figure is modified from He et al. 
(2004) with permission from the Elsevier Limited. 
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Protein secretion by T3SS is Sec-independent. They are transported directly from the 
cytoplasm out of the cell through the trans-envelope needle-like channel. The signal for 
secretion was first reported to be located at the N-terminal 15-17 amino acid residues of the 
proteins traversing the T3SS; however, controversial results showed that the 5’ region of 
mRNAs encoding the secreted proteins actually contained the signal recognized by T3SS 
(Sory et al., 1995; Anderson and Schneewind, 1997 and 1999). The most recent reports 
suggest that the amphipathic peptide sequence, not mRNA, is actually recognized by the 
T3SS machinery (Lloyd et al., 2002). 
 
1.1.3 Type IV secretion system 
The T4SS was firstly known as the ‘adapted conjugation’ system (Christie and Vogel, 
2000). In recent reviews, T4SS members include all conjugation and related systems 
mediating DNA or protein translocation (Christie, 2004). The T4SS apparatus, encoded by 
more than 10 genes, features an envelope-spanning channel and an extracellular pilus 
(mating pair formation structure) that is able to establish direct cell to cell contact. In 
Agrobacterium tumefaciens, the same trans-envelope structure transports both DNA and 
proteins, assisted by different cytoplasmic chaperones (Christie, 2004), as illustrated in Fig. 
3. The apparatus delivers substrates across the envelope in one step to the medium or 
directly into recipient cells. The Bordetella pertussis system is an exception in that it 
transports pertussis toxin in two steps, involving Sec-dependent translocation across the 
inner membrane and T4SS-dependent translocation across the outer membrane. Comparison 
of known T4SS substrates has failed to show a common sequence for secretion. Some 
protein-fusion studies showed that the signal for secretion is located at the C-terminal end of 
secreted proteins. It is further found that many T4SS substrates share an Arginine-rich or 
positive charge-abundant C-terminus. How positive charges are involved in substrate 
recognition is not yet clear. 
 
1.1.4 Type V secretion system 
The T5SS is also known as autotransporter (AT)/two-partner secretion (TPS) pathway, 
which is widely spread especially among pathogenic bacteria (Henderson and Nataro, 2001; 
Jacob-Dubuisson et al., 2001; Jacob-Dubuisson et al., 2004). The AT pathway is the simplest 
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Fig. 3 Model of the T4SS system in A. tumefaciens. The T4SS apparatus is comprised of 
an extracellular pilus (mating pair formation structure) and a trans-envelope channel. In A. 
tumefaciens, the system is able to transport both DNA and proteins, such as D2-T-strand and 
E2 shown in the figure. The figure is modified from Juhas et al. (2008). 
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secretion system in that the substrates can mediate their own secretion across the outer 
membrane (Fig. 4). AT proteins are synthesized with an N-terminal signal peptide, which is 
recognized by the Sec machinery and cleaved after the proteins are transported across the 
inner membrane. They also contain two distinct modules, an N-terminal passenger module 
(following the signal peptide), which performs a specific function after they are secreted, and 
a C-terminal translocation module which functions to transport the passenger module out of 
the cell. It has been suggested that the C-terminal translocation domain is able to insert itself 
into the outer membrane as a β-barrel, in a similar way as porins do, to form a conduit to 
allow passage of the passenger domain. After transport, the passenger domain may remain 
on the cell surface or be released by proteolytic cleavage. The TPS system functions 
similarly as the AT system except that two TPS proteins (TpsA and TpsB) play the roles of 
passenger domain and transport domain, respectively. In addition, TpsA contain a TPS 
domain after the signal peptide which interacts with TpsB for secretion. 
 
1.1.5 Type VI secretion system 
The T6SS is the most recently described and least understood system but is found 
widespread in bacterial pathogens (Bingle et al., 2008). The system is able to establish close 
contact with eukaryotic cells and release effectors directly into the cell. The apparatus is 
comprised of 12 to more than 20 proteins but little is known about the protein-protein 
interactions in the machinery. The current model describes it as a trans-envelope structure 
that delivers protein effectors from the cytoplasm out of the cell or directly into the host cell 
in one step (Cascales, 2008), as shown in Fig. 5. However, some data suggest that the 
secretion may contain two steps because one secreted protein was found to accumulate in the 
periplasm in a T6SS mutant strain (Mougous et al., 2007). One interesting feature of the 
Vibrio cholerae T6SS is that it may assemble an outer membrane needle-like structure that 
shows homology with the bacteriophage T4 base-plate. The needle-like structure is 
comprised of trimeric VgrG and may puncture the host cell and release the activity domain 
of VgrG from the needle tip (Pukatzki et al., 2007). 
 
1.2 The type II secretion system in Gram-negative bacteria 
The type II secretion system (T2SS) has long been known as the main terminal branch
  
 
 
           
Fig. 4 Model of the T5SS system. The AT protein contains a signal peptide (green), which 
is required for transport across the innter membrane via the Sec system, an N-terminal 
passenger domain and a C-terminal transport domain. The transport domain is able to insert 
into the outer membrane as a β-barrel, through which the passenger domain is transported. 
After transport, the passenger domain is folded and may remain on the cell surface or be 
released by proteolytic cleavage. The TPS system functions similarly, except that two 
proteins TpsA and TpsB play the roles of passenger domain and transport domain, separately 
(not shown in the figure). The figure is modified from Wells et al. (2007). 
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Fig. 5 Model of the T6SS system. The T6SS apparatus is proposed to be a multicomponent 
trans-envelope structure that is able to inject protein effectors directly in to host cell. VgrG 
forms a unique trimeric needle-like structure that assembles the bacteriophage T4 base-plate. 
The needle-like structure may puncture into the host cell and release the activity domain 
from the needle tip. The figure is modified from Cascales (2008) with permission from the 
Nature Publishing Group. 
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of the general secretion pathway (GSP), recognized as the main route for extracellular 
protein translocation in Gram-negative bacteria (Pugsley, 1993a; Cao et al., 2003). The GSP 
describes a two-step secretion pathway in which exoproteins cross the inner membrane and 
the outer membrane successively. In the first step, the precursor proteins containing a 
cleavable N-terminal signal peptide are recognized by Sec machinery and transported across 
the inner membrane (Veenendaal et al., 2004). The proteins are processed and fold in the 
periplasm. In the second step, the exoproteins are recognized and transported across the 
outer membrane. The second step is called the terminal branch of the GSP. T2SS is known as 
the main terminal branch, one of several terminal branches identified. Recently, T2SS was 
also demonstrated to be able to secrete Tat-dependent substrates (Voulhoux et al., 2001). The 
T2SS machinery involves 12-16 proteins which assemble into a complex structure, termed 
the secreton, spanning both the inner membrane and the outer membrane. 
The T2SS was first discovered in Klebsiella oxytoca, and called the Pul system 
(d’Enfert et al., 1987). Homologues have since been demonstrated in numerous Gram-
negative bacteria, including Pseudomonas aeruginosa (Xcp system), Erwinia chrysanthemi 
(Out), Vibrio cholerae (Eps) and Aeromonas hydrophila (Exe). Important virulence factors 
of bacterial pathogens are T2SS substrates, for example in the secretion of cholera toxin, the 
major cholera diarrhea-causing factor, by the Eps system of V. cholerae (Spangler, 1992; 
Johnson et al., 2006). Homologous proteins in different systems are named with the same 
letters, e.g. PulC of K. oxytoca is a homologue of EpsC of V. cholerae. The designation of 
the Xcp system in P. aeruginosa is an exception for historical reasons, for example, XcpP is 
a homologue of PulC and EpsC. Currently Gsp is the common name for different T2SSs, for 
example, the above homologues belong to the GspC family. 
The most significant feature of T2SS is that it resembles the type IV pilus biogenesis 
system in that a pilus-like structure, called pseudopilus, is present in the T2SS (Köhler et al., 
2004; Peabody et al., 2003, Vignon et al., 2003). A homologue of type IV prepilin peptidase 
is also required to process the pseudopilins (Nunn and Lory, 1992 and 1993; Pugsley, 1993b). 
In addition, several components of T2SS share similarities in both sequence and structure 
with those of the type IV pilus (see more details below). The two systems are thus proposed 
to have evolved from a same ancestor (Nunn, 1999). 
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1.2.1 Genes encoding Gsp proteins 
The Gsp system is encoded by 12-16 genes that are usually clustered in operons gspC-O, 
gspAB and gspS, as shown in Fig. 6 (Filloux, 2004). gspC-N is conserved in most T2SSs. In 
some bacteria, gspO is substituted by the prepilin peptidase of type IV pilus, for example, 
pilD in P. aeruginosa and tapD in A. hydrophila (Nunn and Lory, 1991; Pepe et al., 1996). 
gspAB and gspS are not present in all bacteria, although they are absolutely required in A. 
hydrophila and K. oxytoca, respectively (Jahagirdar and Howard 1994; Hardie et al., 1996). 
 
1.2.2 Structure of the T2SS machinery 
The complicated trans-envelope structure of T2SS and how this structure is assembled 
are not fully understood yet. The experimental data from protein-proteins interactions 
between T2SS components, subcellular localization, electron microscopy and 
crystallography studies have suggested dissecting the machinery into three parts: an inner 
membrane platform, a periplasmic pseudopilus and an outer membrane channel (Johnson et 
al., 2006). A model of T2SS is illustrated in Fig. 7. 
The inner membrane platform is composed of GspE, F, L and M (Py et al., 2001). GspE 
is a cytoplasmic protein which is associated with the inner membrane platform through 
interactions with the membrane protein GspL (Sandkvist et al., 1995; Py et al., 1999). GspE 
is a member of a large family of secretion nucleoside triphosphatases that contain conserved 
motifs of Walker A box, Walker B box, a histidine box and an aspartate box (Possot and 
Pugsley, 1994). EpsE from V. cholerae has been demonstrated to be a Mg2+-dependent 
ATPase in vitro (Camberg and Sandkvist, 2005). The purified protein formed a small fraction 
of hexamers that showed increased ATPase activity, consistent with the crystallography 
studies in which the protein was modeled into a hexameric ring (Robien et al., 2003). 
Similar hexameric structure was also obtained in the crystallography studies of secretion 
ATPase family members HP0525 of Helicobacter pylori and PilT of the type IV pilus (Yeo 
et al., 2000; Forest et al., 2004). It is likely that the functional form of GspE in vivo is a 
hexameric ring that provides energy for secretion/assembly of the T2SS and/or forms a 
channel to allow transport. Other components of the inner membrane platform are membrane 
proteins GspF, L and M. Interactions among these proteins include GspE-GspL interactions, 
GspL-GspM interactions and GspE-F interactions (Sandkvist et al., 1995; Py et al., 1999; 
  
 
 
 
 
 
 
 
Fig. 6 Genes encoding the T2SSs in K. oxytoca (pul), A. hydrophila (exe), X. campestris 
(xps) and P. aeruginosa (xcp and hxc). Homologous genes are designated with the letters 
A-O and S. P. aeruginosa is an exception, as P-Z and A are used. In A. hydrophila and P. 
aeruginosa, exeO and xcpA are substituted by the type IV pilus prepilin peptidase encoding 
genes tapD and pilD, respectively. The figure is modified from Filloux (2004) with 
permission from the Elsevier Limited. 
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Fig. 7 Model of the T2SS system. The T2SS apparatus is comprised of 12-16 proteins, 
forming an inner membrane platform of GspE-F-L-M, a periplasmic pseudopilus of GspG-
H-I-J-K, and an outer membrane channel GspD secretin. GspC is proposed to connect the 
inner membrane and the outer membrane complexes. GspA and B form an inner membrane 
complex and their assembly in the apparatus will be studied in this study. GspN and S are 
not illustrated. AB5: cholera toxin secreted by the T2SS in V. cholerae. CM: cytoplasmic 
(inner) membrane. OM: outer membrane. The figure is modified from Johnson et al. (2006). 
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Scott et al., 2001; Crowther et al., 2004 and 2005). The inner membrane platform complexes 
of Out and Xcp systems could be co-immunoprecipitated and co-purified, respectively (Py et 
al., 2001; Robert et al., 2005). 
The periplasmic pseudopilus is composed of GspG, H, I, J and K. These proteins share 
sequence and structural similarities with the pilins of type IV pilus and thus are called 
pseudopilins (Nunn and Lory, 1992 and 1993; Pugsley, 1993b). They all have a special N- 
terminal leader peptide for transport across the inner membrane and require GspO or prepilin 
peptidase PilD for processing. GspO and PilD have a high degree of identity. PilD is a 
bifunctional peptidase, cleaving the leader peptide of prepilins and N-methylating the 
generated N-termini before the pilin subunits are assembled into type IV pilus (Lapointe and 
Taylor, 2000). In A. hydrophila and P. aeruginosa that do not contain GspO, the prepilin 
peptidases TapD and PilD, respectively, process both type IV prepilins and T2SS 
pseudopilins (Nunn and Lory, 1991; Pepe et al., 1996). Among the pseudopilins, GspG is 
most abundant, thus called the major pseudopilin; others are minor pseudopilins (Nunn and 
Lory, 1993; Pugsley, 1993b; Hu et al., 2002). Overproduction of GspG resulted in long 
pilus-like structures on the cell surface under transmission electron microscopy (Durand et 
al., 2003). Together with the crystal structure of GspG, the pseudopilus has been modeled 
into a left-handed structure with the hydrophobic N-terminal α-helix of GspG packed into 
the core of the pseudopilus (Köhler et al., 2004). A greater understanding of the roles of the 
minor pseudopilins has been obtained through crystallography studies, especially the crystal 
structure of the heterotrimeric complex of GspI-J-K (Korotkov and Hol, 2008). The 
pseudopilins all contain a conserved N-terminal α-helix, a conserved C-terminal β-sheet and 
a variable region between them. GspK is special in that it contains a large α-helical domain 
in the β-sheet region, preventing upward addition of pseudopilins but allowing downward 
addition of GspI, J and G. The GspJ-I-K complex may thus form the “arrow head” of the 
pseudopilus with the α-helical domain of GspK interacting with the outer membrane channel 
or secreted proteins (Forest, 2008). 
The outer membrane channel is comprised of a 12-14 member multimer of GspD, called 
secretin (Chen et al., 1996; Hardie et al., 1996; Sandkvist, 2001). GspD is a member of the 
secretin family of outer membrane channel-forming proteins required in T2SS, type IV pilus, 
T3SS and filamentous phage extrusion (Genin and Boucher, 1994). They contain a variable 
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N-terminal domain and a highly conserved C-terminal domain. The C-terminal domain 
contains putative amphipathic β-strands that are believed to insert in the outer membrane and 
form the wall of the conduit. One remarkable feature of secretin is that it forms a stable, heat 
and detergent-resistant structure that runs on SDS-PAGE as a mega Dalton band just able to 
enter into the gel (Hardie et al., 1996; Ast et al., 2002). Two T2SS and one phage secretion 
secretins have been characterized by electron microscopy (Bitter et al., 1998; Nouwen et al., 
1999 and 2000; Opalka et al., 2003; Chami et al., 2005). The C-terminal domain of GspD 
forms a proteolysis-resistant 12-14 multimeric ring-like structure with a central pore of 50-
100 Å in diameter which is occluded with a plug. The N-terminal domain of secretin 
protrudes into the periplasm and is proposed to interact with other components of the 
machinery or secreted proteins (Chami et al., 2005). In K. oxytoca and Erwinia species, 
lipoprotein GspS is required for assembly of GspD secretin into the outer membrane and 
probably is a part of the secretin complex through the interactions between GspS and the C-
terminal end of GspD (Hardie et al., 1996; Shevchik and Condemine, 1998). GspD also 
interacts with two inner membrane proteins GspC and GspN, which in turn interact with the 
inner membrane complex GspM-L (Gérard-Vincent et al., 2002; Lee et al., 2004; Possot et 
al., 1999). GspC and GspN may thus have a function of connecting the inner membrane 
platform GspE-F-L-M and the outer membrane GspD secretin. In addition, GspD may 
interact with the inner membrane proteins GspAB. GspA and GspB are not present in all 
T2SSs, although they are absolutely required in A. hydrophila (Jahagirdar and Howard, 
1994). In this bacterium, ExeAB functions to locate/assemble ExeD secretin into the outer 
membrane, a similar role to that of GspS in GspAB-absent bacteria (Ast et al., 2002). The 
assembly of GspD secretin and the roles of GspAB in this process are the main objectives of 
this dissertation and will be addressed in more details in section 1.3.3. 
 
1.2.3 Secretion mechanism of the T2SS 
Protein secretion via the T2SS is a two-step process (Poquet et al., 1993; Sandkvist, 
2001). The exoproteins are first transported across the inner membrane via the Sec or Tat 
pathway and then recognized by the T2SS machinery and transported across the outer 
membrane. In T2SS mutants, the exoproteins are accumulated in the periplasm instead of 
secreted out of the cell (Pugsley et al., 1991; Jiang and Howard, 1991). 
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The mechanism of protein secretion by T2SS is highly specific in two aspects. Firstly, 
the machinery is able to discriminate exoproteins from periplasmic proteins for secretion. 
Secondly, exoproteins of one bacterium are usually not recognized by other bacteria, with a 
few exceptions (de Groot et al., 1991; Wong et al., 1990; Frenken et al., 1993; Gerritse et al., 
1998). This suggests that the proteins targeted by T2SS must contain specific signals for 
secretion. However, the exoproteins do not have identifiable consensus sequences either 
among species or within species except the signal peptide which is cleaved after export via 
the Sec machinery. Fusion protein technology has been used by many researchers to identify 
the secretion signal; however, the results are controversial. For example, a fusion protein 
containing a.a. 60-120 of exotoxin A and the periplasmic β-lactamase was secreted in P. 
aeruginosa (Lu and Lory, 1996). When this region was removed from exotoxin A, however, 
the protein was still secreted (MacVay and Hamood, 1995). One unique feature of the T2SS 
is that exoproteins are folded in the periplasm before secretion (Hirst and Holgmgren, 1987; 
Pugsley et al., 1991; Hardie et al., 1995). It is thus proposed that the signal for secretion 
might therefore be a 3-D structure created during folding of the protein (Sandkvist, 2001). 
The tertiary structure property of a secreted protein, but not the primary structure, may be the 
secretion determinant. To support this notion, the B-subunit of E. coli heat-labile enterotoxin, 
which shares only 11% similarity in sequence but high similarity in tertiary structure with 
the B-subunit of cholera toxin, was secreted by the T2SS of V. cholerae (Connell et al., 
1995).  
The crystal structures of several T2SS-dependent exoproteins have been solved. 
Aerolysin, elastase, lipase, neuraminidase, pectate lysase C and cholera toxin B-subunit do 
not share amino acid similarity and have distinctive functions. They are also very diverse in 
crystal structure and no apparent common structural motif can be identified. One property of 
these structures is that they all have a high content of β-sheet; however, no reliable evidence 
is available to suggest a function for β-sheets during secretion (Sandkvist, 2001). It is 
thought that some physicochemical properties of the structure, such as charge and 
hydrophobicity distribution, might be the important factors for recognition by T2SS (Filloux, 
2004). 
How the T2SS exoproteins find their way to dock at the secretion channel for transport 
is not clear. The finding that the GspD secretin contains a periplasmic structure, comprised 
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of the species-specific N-terminal domain, suggests that it may interact with the exoproteins 
(Chami et al., 2005). The crystal structure of pseudopilin heterotrimeric GspI-J-K indicates 
that they are likely the “arrow head” of the pseudopilus with the α-helical domain of GspK 
on the top (Korotkov and Hol, 2008). It is therefore proposed that the α-helical domain of 
GspK may have a role in the recruitment of exoproteins to the secretin (Forest, 2008). In 
addition, dedicated chaperones may be involved in the docking process (Filloux, 2004). 
The structural similarity between the T2SS pseudopilus and the type IV pilus has 
implied a mechanism for how exoproteins pass through the secretin channel. The type IV pili 
are involved in twitching motility which bacteria use to move on solid surface (Burrows, 
2005). This involves cycles of extension and extraction of the pili, achieved by assembly and 
disassembly of pilin subunits through NTPase PilB and NTPase PilT, respectively, of the 
inner membrane platform (Filloux, 2004; Burrows, 2005). The T2SS pseudopilus is thus 
proposed to have similar actions to a piston, to push exoproteins through the secretin 
(Sandkvist, 2001; Forest, 2008). GspE, shown to be an ATPase, shares high similarity with 
PilB and would probably have the same function (Camberg and Sandkvist, 2005). To support 
the hypothesis, overexpression of the major pseudopilin GspG is found to result in pilus-like 
fibers exposed on cell surface, accompanied by interference with secretion (Hu et al., 2002; 
Sauvonnet et al., 2000; Durand et al., 2003). This implies that GspG is able to assemble into 
a pilus-like structure; the pseudopilus is directed to the secretion channel and may occlude 
the channel upon over-assembly. Alternatively, the pseudopilus may have a function to gate 
the secretin pore rather than actively push the exoproteins (Forest, 2008). Since the pore of 
the secretin is large (50-100 Å) for passage of folded proteins, it is assumed to be closed to 
protect the integrity of the cell except when an open channel is required during transport. 
The retractable pseudopilus may thus control the open or closed status of the secretin. It is 
also likely that the pseudopilus may induce conformational changes in the secretin to open 
the pore through interactions with the secretin once the exoproteins are docked. 
 
1.3 The type II secretion system in A. hydrophila 
1.3.1 Proteins secreted by the T2SS of A. hydrophila 
A. hydrophila is a Gram-negative bacillus well known as a pathogen of many cold 
blooded aquatic animals, whereas occasional infections in mammals have been reported 
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(Hazen et al., 1978; Altwegg and Geiss, 1989). The T2SS of A. hydrophila secretes a variety 
of extracellular protein toxins and degradative enzymes, including aerolysin, amylase, lipase, 
protease and deoxyribonuclease (Jiang and Howard, 1991).  
In particular, aerolysin is an important virulence determinant in rainbow trout and 
mouse infection models (Chakraborty et al., 1987; and Cascon et al., 2000). This toxin is 
synthesized as preproaerolysin with an N-terminal signal sequence. After transport across 
the inner membrane by Sec machinery, the signal sequence is cleaved and the protein folds 
into dimeric proaerolysin. The inactive proaerolysin is secreted by the T2SS to the 
extracellular environment where it matures into active aerolysin by proteolytic removal of a 
C-terminal fragment, either by A. hydrophila-secreted or exogenous proteases (Howard and 
Buckley, 1985). The active dimeric aerolysin is able to bind to eukaryotic cell protein 
receptors that have a common glycosylphosphatidylinositol (GPI) membrane anchor. 
Aerolysin dimers then undergo conformational changes to form heptamers that insert into 
the membranes of the eukaryotic cell, creating large open channels to kill the cell (Buckley, 
1991; Rossjohn et al., 1998). The crystal structure of proaerolysin shows a dimeric structure 
with a high β-sheet content (Parker et al., 1994). Based on electron microscopy, the 
aerolysin heptamer has been modeled into a mushroom-shaped structure with its stalk 
spanning the membrane and a central pore of 17 Å in diameter (Rossjohn et al., 1998).  
In our laboratory, lysis of red blood cells by aerolysin is used as the major method to 
examine the function of T2SS in A. hydrophila. Other secreted proteins including lipase and 
protease are also assayed for functional analysis. 
 
1.3.2 exe operons encoding the T2SS of A. hydrophila 
In A. hydrophila, the gsp genes encoding T2SS components are termed exe genes (Jiang 
and Howard, 1991; Jahagirdar and Howard, 1994). They are clustered at two separate 
chromosomal locations as operon exeC-N and operon exeAB as shown in Fig. 6 (page 12). 
They were identified by complementation studies of aerolysin secretion mutants isolated by 
Tn5-751 transposon insertion mutagenesis. One of the mutant strains is C5.84, which 
contains the insertion in the exeAB operon and is used in this thesis to study the functions of 
ExeAB. The gspO gene is not found with the exe clusters; instead, tapD, encoding the 
prepilin peptidase of type IV pilus, is required to process the T2SS pseudopilins (Pepe et al., 
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1996). In addition, genes encoding homologues of GspS are not found in A. hydrophila. 
 
1.3.3 Roles of ExeA and ExeB in the T2SS of A. hydrophila 
Although homologues of ExeAB are not found in all bacteria, they are essential for 
normal type II secretion in A. hydrophila (Jahagirdar and Howard, 1994). Insertion of Tn5-
751 transposon in exeA eliminated the production of both ExeA and ExeB. However, marker 
exchange mutagenesis confirmed that both of the proteins are required for secretion. 
The hydrophobicity profile as well as cell localization and alkaline phosphatase reporter 
studies showed that both ExA and ExeB are trans-inner membrane proteins with domains 
exposed on the periplasmic and cytoplasmic sides of the membrane (Jahagirdar and Howard, 
1994; Howard et al., 1996). The 60 kDa ExeA is comprised of a 31 kDa N-terminal 
cytoplasmic domain, a short central hydrophobic inner membrane domain and a 28 kDa C-
terminal periplasmic domain. The 25 kDa ExeB resides mainly in the periplasm with only a 
small N-terminal domain exposed on the cytoplasmic side. The two proteins form a complex, 
demonstrated by co-stabilization, cross-linking, co-immunoprecipitation and co-purification 
(Howard et al., 1996; Schoenhofen et al., 1998). 
The role of the ExeAB complex was first implied from the finding that the cytoplasmic 
domain of ExeA contains Walker A and Walker B motifs, which are conserved in Walker 
superfamily of ATPases (Walker et al., 1992; Howard et al., 1996). In addition, this domain 
also contains a motif kinase-3a that is commonly conserved in kinases. Mutagenesis studies 
showed that this putative ATP binding site is required for normal function of ExeA (Howard 
et al., 1996; Schoenhofen et al., 1998). The cytoplasmic domain of ExeA was then purified 
and shown to have ATPase activity in vitro (Schoenhofen et al., 2005). ExeB shares a low 
sequence similarity with TonB, which is required for energy transduction in the uptake of 
siderophores and other molecules across the outer membrane (Howard et al., 1996; 
Krewulak and Vogel, 2008). ExeA and ExeB were thus proposed to act together to transduce 
metabolic energy to the secretion process, for example, in opening the channel of the ExeD 
secretin or in assembly of the secretion apparatus (Howard et al., 1996). However, GspE, a 
critical component conserved in all T2SSs, has also been found to have ATPase activity and 
suggested to provide the energy required for secretion (Camberg and Sandkvist, 2005). It is 
therefore necessary to explain the redundant energy sources in A. hydrophila, especially 
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when GspAB is absent in many T2SSs. It is likely that the energy provided by ExeAB is not 
for the general secretion process, but for an event that can be achieved in distinct ways by 
different bacteria. 
A breakthrough in understanding of the role of ExeAB was provided by the studies of 
Ast et al., 2002. The ExeAB complex was found to play an important role in ExeD secretin 
assembly. In ExeAB mutants, ExeD accumulated in the inner membrane as a monomer 
instead of being assembled into the outer membrane as the multimeric secretin. ExeAB may 
not be involved in the secretion process itself, because when ExeD was overproduced, 
resulting in a few multimers assembled in the outer membrane through leakage or non-
specific pathways, secretion was restored even in the absence of ExeAB. The role of exeAB 
in secretin assembly may be achieved through interactions between ExeA and peptidoglycan, 
a barrier to trans-envelope apparatus assembly, since a putative peptidoglycan-binding motif 
has been identified in the periplasmic C-terminus of ExeA (Howard et al., 2006). Mutations 
at the putative peptidoglycan-binding motif could abolish ExeD secretin assembly and 
therefore aerolysin secretion without abrogation of ExeAB complex formation. The role of 
ExeAB in the assembly of ExeD secretin is therefore proposed to involve local remodelling 
of peptidoglycan, either by direct hydrolysis or interference with normal peptidoglycan 
biogenesis, to allow ExeD to traverse across the peptidoglycan barrier and assemble in the 
outer membrane (Howard et al., 2006).  
Homologues of GspAB are found in some but not all species that have the T2SS. In 
Erwinia species and K. oxytoca, only GspB homologues OutB and PulB, respectively, but 
not GspA homologues, are present (Condemine and Shevchik, 2000; Possot et al., 2000). 
OutB is required for normal secretion. In an OutB mutant, secretion was restored when OutD 
was overproduced, a phenomenon also observed in ExeA mutants of A. hydrophila 
(Condemine and Shevchik, 2000; Ast et al., 2002). PulB, in contrast, was not required for 
pullulanase secretion when the K. oxytoca Pul system was expressed in E. coli (Possot et al., 
2000). However, we have to notice that the pul genes expressed in E. coli were encoded in 
multi-copy plasmids under the control of maltose-inducible promoters. This might cause 
overproduction of PulD, which has been shown to suppress GspAB/B mutations in A. 
hydrophila and E. chrysanthemi (Condemine and Shevchik, 2000; Ast et al., 2002). It is 
therefore necessary to control the expression level of pul genes in order to better understand 
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the role of PulB. GspAB homologues are also found in Vibrio species and E. coli (Francetic 
and Pugsley, 1996; Howard et al., 2006). Their role in the T2SS needs to be further clarified. 
In bacteria that do not have GspA, GspS may perform a similar function. In E. 
chrysanthemi, an OutS mutant failed to insert the OutD secretin into the outer membrane 
(Shevchik and Condemine, 1998).  In addition, OutS was found to interact with the 62 C-
terminal amino acids of OutD. Consistent with this, PulS was reported to play a role in 
piloting PulD secretin into the outer membrane (Hardie et al., 1996; Guilvout et al., 2006). 
The PulS-interacting site was also identified at the 65 C-terminal residues of PulD (Daefler 
et al., 1997). These findings are quite similar to those observed for ExeA of A. hydrophila, 
although GspS and GspA are distinct proteins. GspS is a lipoprotein that is associated with 
the outer membrane (d'Enfert and Pugsley, 1989; Shevchik and Condemine, 1998). It is 
proposed that GspD in the inner membrane is co-sorted into the outer membrane by the 
lipoprotein sorting pathway, a system transporting lipoproteins to the outer membrane 
(Tokuda and Matsuyama, 2004; Guilvout et al., 2006). These facts may therefore explain 
why GspA is not required in these bacteria. In bacteria that do not have GspA and GspS, for 
example, X. campestris and P. aeruginosa, other pathways may be involved in sorting GspD 
into the outer membrane. 
The exact role(s) of GspAB and GspS are not clear. Do they solely translocate the GspD 
into the outer membrane or are they also involved in assembly of the secretin? It has been 
reported that PulD was able to insert into the inner membrane and formed ring-like particles 
corresponding to the secretin as viewed by electron microscopy (Guilvout et al., 2006). They 
further showed that PulD inserted and formed secretin-like structures in lecithin lipids when 
the protein was produced in a cell-free in vitro transcription–translation system (Guilvout et 
al., 2008). It was therefore concluded that PulD has an inherent ability to insert as multimers 
into lipid bilayers. However, we have to note that these findings were based on 
overexpression of PulD either in vivo or in vitro. They might therefore not present the 
physiological facts in vivo. A few reports indicate that the assembly of the T2SS secretin 
requires other factors. One of these factors is the outer membrane protein Omp85/YaeT, 
which is required for general outer membrane protein insertion and/or multimerization, for 
example, for porins, TolC and the PilQ secretin (Voulhoux et al., 2003; Doerrler and Raetz, 
2005; Werner and Misra, 2005). Other factors include outer membrane lipoproteins QilW 
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and Tgl, which are required for PilQ secretin assembly in Neisseria meningitides and 
Myxococcus xanthus, respectively (Carbonnelle et al., 2005; Nudleman et al., 2006). 
Lipoprotein YscW homologues are required for T3SS secretin assembly (Daefler and 
Russel, 1998; Crago and Koronakis, 1998; Burghout et al., 2004; Cornelis, 2006). In 
addition, special components of the outer membrane, such as lipopolysaccharide (LPS), may 
be involved in the assembly process. 
 
1.4 Peptidoglycan as a barrier in trans-envelope apparatus assembly 
1.4.1 Structure of peptidoglycan 
Peptidoglycan, also known as murein, is a net-like structure made of glycan strands 
cross-linked by short peptides and can be hydrolyzed by mutanolysin or other N-
acetylmuramidases into N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) disaccharide peptide subunits called muropeptides (Schleifer and Kandler, 1972; 
Glauner, 1988; Nakimbugwe et al., 2006). The sugars are linked with β-1,4 glycosidic bonds. 
The peptides are distinctive in that they contain D-amino acid residues not found in proteins. 
Certain modifications or variations may be present in peptidoglycan, for example, N-
deacetylation, O-acetylation, N-glycolylation, peptide cross-linking variations and number of 
layers (Vollmer et al., 2008). The structures of E. coli peptidoglycan and the commonest 
muropeptide disaccharide tetrapeptide are illustrated in Fig. 8. Peptidoglycan usually 
contains meso-2,6-diaminopimelic acid (m-A2pm or m-DAP) to D-Ala cross-links and is a 
multi-layer structure located outside of the cytoplasmic membrane in Gram-positive bacteria,  
a thin layer in the periplasm in Gram-netative bacteria. One exception is Staphylococcus 
aureus, in which the peptidoglycan contains Lys-penta-Gly cross-links. 
 
1.4.2 Biosynthesis of peptidoglycan 
Peptidoglycan is assembled with disaccharide muropeptide units (reviewed by Höltje, 
1998). The precursors of muropeptide are synthesized via a linear pathway of 12 steps from 
fructose-6-P to lipid intermediates in the cytoplasm (reviewed by van Heijenoort, 2007). The 
lipid intermediates include Lipid I and Lipid II. Lipid I is comprised of MurNAc-
pentapeptide linked with diphosphate undecaprenyl. The hydrophobic undercaprenyl moiety
  
 
 
 
 
 
 
 
 
 
Fig. 8 Structures of E. coli peptidoglycan and muropeptide. A. Net-like peptidoglycan 
structure with a peptidoglycan synthesis complex in the “three-for-one” model. The shaded 
triple glycan strands beneath the synthesis complex are newly synthesized and replace the 
top existing glycan strand called the docking strand. TG, transglycosylase; TP/TG, 
bifunctional transpeptidase-transglycosylase; TP, transpeptidase; EP, endopeptidase; LT, lytic 
transglycosylase. B. Glycan strands of alternating N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) disaccharide peptides (muropeptides) cross-linked by m-
A2pm-D-Ala peptide bonds. m-A2pm, 2,6-diaminopimelic acid. C. Structure of the most 
abundant muropeptide disaccharide tetrapeptide. The figures are modified from Höltje 
(1998), Scheffers and Pinho (2005) and Vollmer and Bertsche (2008) with permissions from 
the American Society for Microbiology and the Elsevier Limited. 
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is anchored in the cytoplasmic membrane, with the hydrophilic moiety MurNAc-
pentapeptide facing the cytoplasm. Addition of GlcNAc to the MurNAc of Lipid I yields 
Lipid II, which is then transferred by an unknown pathway or flipase across the cytoplasmic 
membrane with the disaccharide pentapeptide moiety exposed to outside of the membrane 
for peptidoglycan assembly. 
Polymerization of the disaccharide muropeptide involves two major reactions: 
transglycosylation for synthesis of glycan stands and transpeptidation for formation of 
peptide cross-links (reviewed by Höltje, 1998). The two reactions are catalyzed by 
transglycosylases and transpeptidases, respectively. One interesting fact is that bacteria have 
multiple enzymes that carry one or both of the above activities, for example, monofunctional 
transglycosylase (TG), monofunctional transpeptidase (TP), bifunctional transglycosylase 
and transpeptidase (TG/TP). In addition, peptidoglycan lytic enzymes are also required for 
release and recycling of old peptidoglycan and shape control of the peptidoglycan sacculus. 
These enzymes include D,D-endopeptidase (EP), D,D-carboxypeptidase (CP), lytic 
transglycosylase (LT) and other lytic enzymes. It has been questioned why bacteria have so 
many “redundant” enzymes in peptidoglycan biosynthesis, as illustrated by the presence of 
12 penicillin-binding proteins (PBPs) in E. coli (Macheboeuf et al., 2006). PBPs, which have 
long been the targets of penicillin and other β-lactam antibiotics, are transpeptidases, 
endopepidases and carboxypeptidases that recognize and act on the D-Ala-D-Ala moiety of 
muropeptides, which share a similar structure with β-lactam antibiotics (Fisher et al., 2005). 
The functions of these enzymes are not the subject of this thesis, but the complexity of the 
structure, modifications and enzymology illustrate that the biogenesis of peptidoglycan is not 
a simple process and that peptidoglycan is not a homogenous structure. Peptidoglycan 
synthesis, hydrolysis and modification are dynamic activities involved in cell elongation, 
septation and trans-envelope structure assembly. 
The well-accepted model for murein growth is the “three-for-one” model (Höltje, 1998). 
In this model, new triple glycan strands are synthesized and attached underneath an existing 
glycan strand called the docking strand, followed by removal of the docking strand by 
hydrolases to insert of the triplet (Fig. 8A, page 23). The insertion of three glycan strands 
and removal of one docking strand enable the cell to double in length if every second glycan 
strand serves as a docking strand. This model follows the principle of “make-before-break”, 
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in which new peptidoglycan should be synthesized before old peptidoglycan is removed in 
order to maintain cellular integrity (Koch, 1995). It also explains the high murein turnover 
rate in which half of the peptidoglycan is broken down in each cell generation in E. coli 
(Goodell, 1985). The major peptidoglycan synthesis is proposed to be carried out by a 
membrane-bound multi-enzyme complex, comprised of transglycosylase, transpeptidase, 
bifunctional transglycosylase/transpeptidase, endopeptidase and lytic transglycosylase for 
different functions, such as synthesis of the central glycan strand of the triplet, synthesis of 
the side glycan strands of the triplet and attachment of the triplet to the docking strand by 
formation of peptide cross-links and removal of the docking strand (Höltje, 1998). The 
complex may include different enzymes for peptidoglycan synthesis at different cell 
locations (septum and pole) and interact with the cell cytoskeleton for cell shape 
maintenance (Scheffers and Pinho, 2005). 
During the synthesis of new glycan strands, Lipid II is used as the substrate to attach the 
disaccharide pentapeptide via β-1,4 glycosidic bond to the growing glycan strand that will 
reach a mean length of 25-35 disaccharide units in E. coli (Harz et al., 1990). Glycan strand 
growth is terminated by cleavage of the diphosphate undecaprenyl moiety and release of the 
glycan strand with a 1,6-anhydroMurNAc end. It should be noted, however, that 
peptidoglycan synthesis is a continuous progress in growing cells. According to the “three-
for-one” model, if glycan strands are evenly synthesized during cell life, three of every five 
glycan strands (including the non-docking stand) are immature and still linked with the lipid 
moiety. Given the average length of glycan strands in E. coli, 1.7%-2.4% of muropeptides 
are linked with the lipid moiety. Taking into account that bacterial cells have two growth 
phases of elongation and septation, the actual amount of lipid moiety-linked muropeptides 
may be lower than the above numbers; however, they should not be neglected in 
peptidoglycan-related studies. 
 
1.4.3 The peptidoglycan barrier in protein transport and large apparatus assembly 
The rigid peptidoglycan structure is essential to protect the cell from osmotic burst; 
however, it also presents a problem in the transport of proteins or the assembly of large 
trans-envelope machineries (Dijkstra and Keck, 1996). In E. coli, the holes of peptidoglycan 
are believed no larger than 4 nm and can only pass globular proteins smaller than 50 kDa 
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(Demchick and Koch, 1996). It was therefore postulated that local hydrolysis of 
peptidoglycan could be involved in assembly of a trans-envelope apparatus and transport of 
macromolecules (Koraimann, 2003). To support this hypothesis, many peptidoglycan 
hydrolyzing proteins have been found to play such a function, for example, FlgJ in flagellar 
assembly, P19 in conjugation system, PleA in pili assembly and PtlE in T4SS (Nambu et al., 
1999; Hirano et al., 2001; Bayer et al., 2001; Pucciarelli and Garcia-del Portillo, 2003; 
Viollier and Shapiro, 2003). In addition, protein-peptidoglycan interactions were also 
reported in T3SS (Rambow-Larsen and Weiss, 2002). To create gaps on peptidoglycan 
should also be involved in T2SS apparatus assembly, for example, the role of ExeAB to 
allow ExeD traverses into the outer membrane where the secretin is assembled (Howard et 
al., 2006). 
It should be noted that direct hydrolysis of peptidoglycan by these assembly-specific 
enzymes, for example, FlgJ and other lytic transglycosylases, is a simple way but not the 
only way to create gaps on peptidoglycan (Koraimann, 2003; Scheurwater et al., 2008). 
Some non-hydrolytic proteins may play such a role by recruiting peptidoglycan-lytic 
enzymes to the assembly site. Alternatively, locally inhibition of peptidoglycan-synthetic 
enzymes may generate gaps during peptidoglycan growth. Other routes may include 
modification of peptidoglycan to change its susceptibility to lytic and synthetic enzymes.      
 
1.5 Purpose of this dissertation 
The previous studies in Dr. Howard’s laboratory have shown that the role of ExeAB in 
the T2SS of A. hydrophila is to locate and/or assemble the ExeD secretin into the outer 
membrane (Ast et al., 2002). The C-terminal domain of ExeA was found to contain a 
putative peptidoglycan binding motif. Mutagenesis of this motif abolished the normal 
function of this protein without interfering with ExeAB complex formation (Howard et al., 
2006). The ExeA-peptidoglycan interactions were thus proposed to play a role in the 
assembly of ExeD secretin. The focus of this research is to use biochemical and 
bioinformatical approaches to examine the interactions between ExeA and peptidoglycan in 
vivo and in vitro. In addition, the interactions between ExeA and other Exe components are 
also addressed. 
2. EXPERIMENTAL PROCEDURES 
2.1 Bacterial strains, plasmids and culture conditions 
A. hydrophila Ah65 is the prototypical wild type stain used in our laboratory and in this 
thesis. Its derivative C5.84 is an exeA::Tn5-751 insertion mutant that is unable to produce 
ExeA (Jahagirdar and Howard, 1994). Because of a polar effect, this strain cannot produce 
ExeB either. E. coli BL21 (DE3) was used for expression of constructed C-
terminal/periplasmic domains of ExeA and its derivatives (pExeAs). E. coli XL1-Blue was 
used for production of plasmid constructs. For purification of peptidoglycan, A. hydrophila 
C5.84, E. coli BL21 and Bacillus subtilis ATCC 6633 were used. See Table 1 for a complete 
list of strains. 
Plasmid constructs encoding exeAB were pRJ31.1 (wild type, Jahagirdar and Howard, 
1994 ) and pCGs that contain substitution mutations for three highly conserved amino acids 
in the putative peptidoglycan binding motif in the C-terminal domain of ExeA (pCG1: 
F487S, pCG2: L493S and pCG3: G500D, Howard et al., 2006), with IPTG inducible 
promoters in the wild-host-range vector pMMB207 (Morales et al., 1991). Plasmid 
constructs encoding His tagged wild type and mutant pExeAs are pN-His-pExeA, pC-His-
ExeA, pN-His-pCGs and pC-His-pCGs in pET30a vector with an IPTG inducible promoter 
(This study). See Table 2 for a complete list of plasmids. 
A. hydrophila strains were grown at 30 ºC to an OD600 of 1.8-2.0 in Luria-Bertani (LB) 
media buffered with 30 mM Na2HPO4, 30 mM K2HPO4, 16.5 mM NaH2PO4, 16.5 mM 
KH2PO4, 0.75 mM (NH4)2SO4 and 0.4 mM MgSO4 in cross-linking studies (Ast et al., 
2002). IPTG (0.04 mM) was added to induce plasmid-encoded ExeAB. For production of 
pExeAs, E. coli was grown at 35 ºC in 2xYT media to an OD600 of 0.6-0.8 and induced for 
two hours by adding 0.4 mM IPTG. For purification of peptidoglycan, A. hydrophila, E. coli 
and B. subtilis were grown in 2xYT to an OD600 of 1.5-1.8 at 30 ºC (A. hydrophila) or 37 ºC. 
Appropriate antibiotics were used at the following concentrations: ampicillin (Ap), 100 μg 
ml-1; chloramphenicol (Cm), 1.25 μg ml-1; kanamycin (Kn), 50 μg ml-1; tetracycline (Tc), 10 
μg ml-1. 
 
2.2 Construction of pexeA plasmids 
DNA fragments encoding N-His tagged and C-His tagged pExeAs were amplified by
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Table 1. Bacterial strains used in this study. 
Strain Genotype/phenotype Source 
A. hydrophila 
  Ah65 
  C5.84 
 
Wild type; Nalr; Str; Apr 
Ah65 exeA::Tn5-751; Kmr; Nalr; Str; Apr 
 
This laboratory 
This laboratory 
E. coli 
  BL21 (DE3) 
  XL1-Blue 
F- ompT hsdSB(rB-mB-) gal dem (DE3) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F’ proAB lacIqZΔM15 Tn10]; Tcr 
 
Novagen* 
Stratagene* 
 
B. subtilis 
  ATCC 6633 
 
Wild type 
Dept. Microbiology and 
Immunology, U of S 
Navagen*, Madison, USA; Stratagene*, La Jolla, USA. 
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 Table 2. Plasmids used in this study. 
Plasmid Description Source 
PMMB207 Low-copy-number, wide-range-host plasmid; 
tac promoter; Cmr 
Morales et al., 1991 
pBluescript II 
SK/KS+ 
High-copy-number phagemid; lac promoter; 
Apr 
Stratagene 
pET30a oriColE1; T7lac promoter; Kmr Novagen 
pRJ31.1 exeAB 2.5 kb BstX1 in SmaI of pMMB207 Jahagirdar and 
Howard, 1994 
pCG1 exeA F487S of pRJ31.1 Howard et al., 2006 
pCG2 exeA L493S of pRJ31.1 Howard et al., 2006 
pCG3 exeA G500D of pRJ31.1 Howard et al., 2006 
pN-His-pExeA N-His pexeA NdeI-XhoI PCR fragment from 
pRJ31.1 in pET30a 
This study 
pN-His-pCG1 N-His pexeA F487S NdeI-XhoI PCR fragment 
from pCG1 in pET30a 
This study 
pN-His-pCG2 N-His pexeA L493S NdeI-XhoI PCR fragment 
from pCG2 in pET30a 
This study 
pN-His-pCG3 N-His pexeA G500D NdeI-XhoI PCR 
fragment from pCG3 in pET30a 
This study 
pC-His-pExeA C-His pexeA NdeI-XhoI PCR fragment from 
pRJ31.1 in pET30a 
This laboratory 
pC-His-pCG1 C-His pexeA F487S NdeI-XhoI PCR fragment 
from pCG1 in pET30a 
This study 
pC-His-pCG2 C-His pexeA L493S NdeI-XhoI PCR fragment 
from pCG2 in pET30a 
This study 
pC-His-pCG3 C-His pexeA G500D NdeI-XhoI PCR 
fragment from pCG3 in pET30a 
This study 
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PCR with Pfu DNA polymerase (Fermentas, Burlington, Canada) from pRJ31.1 or pCGs 
with the following primers. NdeI, XhoI, hexa Histidine-tag, and stop codon are underlined 
accordingly. 
For N-His tagged,  
US18 (lig) 5’-CATATGCACCATCATCATCATCATCAGTTCTTCGGCTTCTTCCCC 
UR154 5’-CTCGAGTCAGGAAGCCTCCTCCGACAATGTG 
For C-His tagged, 
UR156 5’-CATATGCAGTTCTTCGGCTTCTTCCCCGAAC 
UR124 5’-CTCGAGGGAAGCCTCCTCCGACAATGTGAC  
The PCR was performed with the following program: 95 ºC for 1 min, 55 ºC for 1 min 
and 72 ºC for 1 min, 28 cycles, followed by 72 ºC for 3 min. After agarose-purification, the 
PCR fragments were inserted into pBluescript II SK+ vectors with blunt ends at the EcoRV 
site by T4 DNA ligase (Invitrogen, Carlsbad, USA). The ligation mixtures were 
electroporated to E. coli XL1-Blue cells and screened for white colonies on LB agar plates 
supplemented with IPTG and X-gal. The recombinant plasmids were extracted and the NdeI-
XhoI fragments cut out with the restriction enzymes, followed by insertion of the agarose-
purified fragments into pET30 vectors and electroporation into XL1-Blue cells. The 
recombinant plasmids, as identified by restriction digestion, were sequenced to rule out the 
possibility of unwanted mutations and then electroporated into E. coli BL21 (DE3) cells for 
protein production. The plasmid construct for C-His pExeA was made by Melody Harrington, 
a former summer student in Dr. Howard’ laboratory. Minipreparations of plasmid DNA were 
obtained using the alkaline lysis method (Sambrook et al., 1989). PCR and restriction DNA 
fragments were isolated in 0.8 % agarose gels and purified with an Ultraclean 15 kit (Mo Bio 
Laboratories, Carlsbad, USA). 
 
2.3 Purification of pExeAs 
E. coli BL21 (DE3) containing pexeA plasmids were grown at 35 °C to an OD600 of 0.6-
0.8 and induced with 0.4 mM IPTG. After two hours, the bacteria were harvested by 
centrifugation and stored at -20 °C. The pellets were resuspended in NTA buffer A (20 mM 
Tris, pH 8.0, 250 mM NaCl, 10 mM imidazole and 10% glycerol) at 10 ml per 200 ml cell 
culture. After addition of 100 µg/ml RNase, 1 µg/ml DNase and 1 protease inhibitor cocktail 
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tablet (Roche, Mississauga, Canada) per 50 ml cell resuspension, the cells were disrupted by 
two passes through a French Press at 14,000 lb/in2, followed by centrifugation at 40,000 x g 
for 40 min to separate the pExeA-containing supernatants from cell debris. The samples 
were applied to HisTrap affinity columns (GE Healthcare, Giles, UK) and pExeAs were 
eluted with a gradient of NTA buffer B (20 mM Tris, pH 8.0, 250 mM NaCl, 500 mM 
imidazole and 10% glycerol). After desalting into ion exchange buffer A (20 mM Tris, pH 
8.0, 25 mM NaCl, 0.2 mM PMSF, 1 mM EDTA and 10% glycerol), the samples were 
applied to a Resource Q column (GE Healthcare), eluted with a gradient of ion exchange 
buffer B (20 mM Tris, pH 8.0, 500 mM NaCl, 0.2 mM PMSF, 1 mM EDTA and 10% 
glycerol). The chromatography was performed on a FPLC system (GE Healthcare) at 4 °C. 
The protein preparations were examined by SDS-PAGE for purity. Protein concentrations 
were determined by measuring absorbance at UV280 with theoretical extinction coefficients 
obtained with ProtParam software. The proteins were stored at 4 °C and used in in vitro 
studies. 
 
2.4 SDS-PAGE, CBB staining and immunoblotting 
Protein samples were electrophoresed on 12% SDS-PAGE gels (Laemmli, 1970), 
except that 10% gels were used for cross-linked samples. For Coomassie Brilliant Blue R250 
(CBB) staining, the gels were soaked in stain solution (0.125% CBB, 25% v/v isopropanol 
and 10% v/v acetic acid) for half an hour, followed by destain solution 1 (0.0025% CBB, 
25% isopropanol and 10% acetic acid) for one hour, destain solution 2 (0.0005% CBB, 10% 
isopropanol and 10% acetic acid) overnight and destain solution 3 (10% acetic acid) until the 
background was destained satisfactorily. For immunoblotting, proteins were transferred to 
PVDF membranes in cold Tris-glycine transfer buffer containing 20% methanol. 
Visualization of transferred proteins was achieved by blocking the membranes in 5% casein, 
incubating with appropriate rabbit antisera, incubating with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (Sigma) and developing with HRP chemiluminescent 
substrate luminal and enhancer (SuperSignal West Pico kit, Pierce, Rockford, USA) or ECL 
Advance (ECL Advance kit, GE Healthcare). 
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2.5 In vivo cross-linking 
Cleavable cross-linker 3,3´-dithiobis[sulfosuccinimidylpropionate] (DTSSP, Pierce) 
was used for cross-linking analysis of ExeA and peptidoglycan in vivo. A. hydrophila cells 
grown to an OD600 of 1.8-2.0 were washed and resuspended in phosphate buffered saline 
(PBS, pH 7.5), and adjusted to an OD600 of 2.0. Concentrated fresh DTSSP solutions were 
made in 5mM sodium citrate (pH 5.0) and added to a final concentration of 0.5 mM 
(Schoenhofen et al., 1998). The cross-linking mixtures were incubated at room temperature 
for 0 to 10 min and quenched by adding 50 mM Tris (pH 8.0). The cross-linked cells were 
added to an equal volume of boiling 8% SDS solution and incubated for 15 min in a boiling 
water bath. After cooling to room temperature, the samples were ultracentrifuged at 130,000 
x g for one hour at room temperature to pellet peptidoglycan (Hancock and Poxton, 1998). 
The pellets were resuspended in water and the SDS-washing step was repeated two 
additional times. The peptidoglycan samples were resuspended in water to 10% of the 
original culture volume. Before loading on SDS-PAGE gels, the whole cell and 
peptidoglycan samples were mixed with 2 x SDS sample buffer containing 0 or 10% β-
mercaptoethanol and heated at 95 °C for 5 min. 
 
2.6 Purification of peptidoglycan 
A. hydrophila C5.84 cells were grown in 2xYT at 30 °C to an OD600 of 1.8-2.0. To 
purify non-denatured peptidoglycan, the cells were disrupted by one pass through a French 
Press at 14,000 lb/in2 (psi), followed by a low speed spin of 5,000 x g for 15 min to remove 
unbroken cells and a high speed spin of 40,000 x g for one hour to pellet cell envelopes 
(Sprott et al., 1994). The cell envelopes were washed with 2% Triton X-100 containing 
20 mM MgCl2 and then 2% Triton X-100 containing 5 mM EDTA to remove membrane 
lipids (Schoenhofen et al., 1998). After each wash, peptidoglycan was collected by 
ultracentrifugation at 130,000 x g for one hour. After four washes with water, the 
peptidoglycan was resuspended in water and stored at 4 °C. All these steps were performed 
at 4 °C to reduce peptidoglycan autolysis. 
Boiling SDS and pronase treated peptidoglycan samples were prepared as described by 
Glauner, 1988 with some modifications. A. hydrophila or E. coli cells were resuspended in 
10 ml boiling 4% SDS solution per 250 ml cell culture and incubated with boiling for one 
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hour with vigorous stirring. After standing at room temperature overnight with continuous 
stirring, the peptidoglycan was collected by ultracentrifugation at 130,000 x g for one hour, 
followed by an additional wash in boiling 4% SDS for 15 min. The peptidoglycan pellets 
were washed four times with water to remove SDS, followed by resuspension in 10 ml water 
per litre cell culture and incubation with 100 µg/ml α-amylase (Roche) in 10mM Tris (pH 
7.0) at 37 °C for two hours to remove glycogen trapped in the peptidoglycan sacculi. Pre-
incubated pronase was then added to a final concentration of 200 µg/ml and the samples 
incubated at 60 °C for 90 min to hydrolyze proteins associated with the peptidoglycan. The 
pronase (Roche) was pre-incubated at 60 °C for two hours to inactivate possible muramidase 
contamination. The samples were treated with boiling 4% SDS solution for 15 min. After 
four washes with water, the peptidoglycan pellets were resuspended in water and stored at 4 
°C. All of the above steps were performed at room temperature unless otherwise indicated to 
avoid SDS precipitation. 
B. subtilis peptidoglycan was purified as described by Bacher et al. (2001) with some 
modifications. The cells were washed with boiling 4% SDS solution as described in A. 
hydrophila peptidoglycan purification except that the peptidoglycan was collected by 
centrifuge at 40,000 g. After four washes with water, the samples were treated with 2 mg/ml 
pre-incubated pronase in 50 mM Tris (pH 7.0) at 60 °C for 90 min. After one wash with 
water, the pellets were resuspended in 2 ml concentrated hydrofluoric acid per litre cell 
culture and incubated overnight on ice to remove anionic polymers such as lipoteichoic, 
teichoic and teichuronic acids covalently bound to peptidoglycan. The hydrofluoric acid was 
neutralized by adding 12 volumes of cold 2 M KOH solution and briefly cooled on ice, due 
to heat generated in the neutralization reaction. The samples were washed three times with 
water to remove the salts and then incubated with 10 µg/ml RNase and 10 µg/ml DNase in 
10 ml 50 mM Tris (pH 7.5) with 2.5 mM MgCl2 and 0.2 mM CaCl2 per litre cell culture to 
degrade nucleic acids trapped in the peptidoglycan sacculi. The enzymes and degraded 
nucleic acids were removed by one wash with boiling 1% SDS solution at 100 °C for 15 
min. After four washes with water, the peptidoglycan pellets were resuspended in water and 
stored at 4 °C. All of the above steps were performed at room temperature unless otherwise 
indicated to prevent SDS precipitation. 
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2.7 Muramic acid assay of peptidoglycan 
Peptidoglycan was quantitated by measuring its muramic acid content with the method 
of Hadzija (1974), modified by Hoijer et al. (1995). 80 μl peptidoglycan samples were 
hydrolyzed with an equal volume of 5 M H2SO4 at 90 °C for two hours. After adding 360 μl 
H2O and 140 μl 10 M NaOH, the samples were incubated at 37 °C for 30 min to release 
lactic acid from the muramic acid residues of the peptidoglycan. The lactic acid 
concentration was then assayed in the following colorimetric reaction. Samples of 300 μl 
were moved to new glass tubes in duplicate. After 2 ml concentrated H2SO4 (18.8 M) was 
added, the tubes were incubated in a boiling water bath for 5 min and then cooled in a room-
temperature water bath. CuSO4·5H2O (20 μl 4% w/v in H2O) and 4-phenylphenol (Sigma, 40 
μl 1.5% w/v in ethanol) were added, followed by incubation at 30 °C for 30 min to develop a 
blue colour measured at 570 nm wavelength. Muramic acid (Sigma) solutions (0 to 1 mM) 
were used as standards. The assays were performed in duplicate and the average absorbance 
was used to calculate muramic acid concentrations, except for the assays of peptidoglycan 
gel filtration fractions, in which single measurement was used. 
 
2.8 Cosedimentation and cosedimentation inhibition assays 
100 μM muramic acid units of peptidoglycan preparations were incubated with purified 
pExeA proteins of various concentrations in 150 µl 40 mM sodium phosphate buffer (pH 
6.5), 0.05% Tween 20 and 10 µg/ml bovine albumin at 4 °C for one hour. The mixtures were 
centrifuged at 21,000 x g at 4 °C for one hour to pellet the peptidoglycan. The mixture, 
supernatant and pellet samples were applied to SDS-PAGE gels and immunoblotted with 
ExeA antiserum. In cosedimentation inhibition assays, pExeA proteins were incubated with 
peptidoglycan fragments at 4 °C for one hour before intact A. hydrophila peptidoglycan was 
added. 
 
2.9 Dynamic Light Scattering 
Dynamic Light Scattering (DLS) was carried out on a Protein Solutions/DynaPro 
instrument (Wyatt, Santa Barbara, USA) at the Saskatchewan Structure Science Centre 
(SSSC). N-His pExeA (2 mg/ml) in 40 mM sodium phosphate (pH 6.5 or 8.0) and 150 mM 
NaCl were filtered through 10 μm membranes before being added to the cuvette. 
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Measurements were performed at a range of temperatures from 4 ºC to 37 ºC with 5 min 
incubation at each temperature. At least 20 valid readings were recorded for each 
measurement. The protein sample was also incubated at 37 ºC for one hour for 
multimerization analysis by DLS. The average particle size was calculated with Dynamics 
software. The particle size distribution was analyzed with DynaLS software. 
 
2.10 Gel filtration chromatography 
All gel filtration experiments were performed at 4 °C with a flow rate of 0.5 ml/min on 
a FPLC system (GE Healthcare). For self-multimerization studies, 2 mg/ml N-His pExeA in 
40 mM sodium phosphate (pH 6.5) and 150 mM NaCl was incubated at 37 °C for one hour, 
followed by incubation at 4 °C overnight. 0.5 ml samples were applied to a Superdex 200 
10/300 GL column (GE Healthcare) in the same buffer. For gel filtration of peptidoglycan 
fragments, 1ml of 7 mM muramic acid units of B. subtilis peptidoglycan were hydrolyzed by 
1,000 units of mutanolysin from Streptomyces globisporus (Sigma) in 40 mM sodium 
phosphate (pH 6.5) at 37 °C overnight, followed by incubation at 95 °C for 20 min to 
inactivate the enzyme. Insoluble material was removed by centrifugation at 21,000 x g at 4 
°C for one hour. 0.5 ml of the supernatant that contained peptidoglycan fragments was 
applied to a Superose 6 10/300 GL column (GE Healthcare) in the same buffer and 
fractionated into 0.5 ml fractions. For multimerization of pExeA in the presence of intact 
peptidoglycan, N-His pExeA (42 nM) was incubated with 250 µM muramic acid units of A. 
hydrophila peptidoglycan in 40 mM sodium phosphate (pH 6.5) and 0.05% Tween 20 at 
room temperature for one hour, followed by incubation with 50 µg/ml lysozyme at room 
temperature for four hours. After centrifugation at 21,000 x g for one hour to remove 
unhydrolyzed peptidoglycan, 0.5 ml of the sample or the non-peptidoglycan control were 
applied to a Superdex 200 10/300 GL column (GE Healthcare) in the same buffer and 
fractionated into 0.5 ml fractions. The fractions were then immunoblotted to determine the 
pExeA distribution. For multimerization of pExeAs in the presence of peptidoglycan 
fragments, 80 nM protein concentrations were incubated with the peptidoglycan gel filtration 
fractions 38-40 (200 µl of each, total 650 µl) in 40 mM sodium phosphate (pH 6.5) and 
0.05% Tween 20 at 4 °C for one hour. 0.5 ml of the mixtures were applied to a Superose 6 
10/300 GL column (GE Healthcare) in the same buffer and collected into 1 ml fractions. The 
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fractions were immunoblotted to determine the pExeA distribution. Both of the columns 
were calibrated with a molecular weight marker kit (Sigma). 2000 kDa: blue dextran; 669 
kDa: thyroglobulin (bovine); 440 kDa: apoferritin (horse spleen); 200 kDa: β-amylase 
(sweet potato); 150 kDa: alcohol dehydrogenase (yeast); 66 kDa: bovine serum albumin; 29 
kDa: carbonic anhydrase (bovine erythrocytes); 12.4 kDa: cytochrome c (horse heart). 
 
2.11 Native gradient PAGE 
Native gradient PAGE was performed as described by Schagger (2001) with some 
modifications. The electrophoresis was run in a Mini-PROTEAN II system (Bio-Rad, 
Hercules, USA). Three-stage gradient acrylamide gels were made by adding the following 
solutions in sequence. A: 2.5 ml 18% T, B: 0.5 ml 1:1 mixed 18% T + 3% T, C: 3% T. 18% 
T and 3% T were prepared with 30% T 3% C (T = Total acrylamide-bisacrylamide; C = 
Crosslinker bisacrylamide)  solution and 6 x gel buffer (150 mM imidazole, adjusted to pH 
7.0 with HCl). 18% T also contained 20% glycerol. After polymerization was complete, the 
gels were electrophoresed at 4 °C. N-His pExeA samples were mixed with 2 x sample buffer 
containing 100 mM imidazole/HCl, pH 7.0, 0.002% Coomassie Blue G-250 and 20% 
glycerol before loading. The anode buffer contained 25 mM imidazole/HCl, pH 7.0 and the 
cathode buffer contained 50 mM Tricine and 7.5 mM imidazole (resulting in a pH of 
approximately 7.0). For the electrophoresis, 100 V was applied for two hours. The proteins 
were visualized by Coomassie Brilliant Blue staining as described for SDS-PAGE gels. 
 
2.12 In vitro cross-linking 
N-His pExeA (60 nM) was incubated with 10 μl peptidoglycan gel filtration fragments 
in 15 μl 40 mM sodium phosphate (pH 6.5) and 0.05% Tween 20 at 4 °C for one hour. After 
an equal volume of 50 mM sodium phosphate, pH 8.5 containing 0 to 5 mM DTSSP (Pierce) 
was added, resulting in a final pH of 7.2, the mixtures were incubated on ice for 30 min and 
mixed with 2 x SDS-PAGE sample buffer (no β-mercaptoethanol added) to stop the cross-
linking. The samples were applied to 10 % SDS-PAGE gels, transferred to poly vinylidene 
difluoride (PVDF) membranes and immunoblotted with ExeA antiserum. 
3. RESULTS 
3.1 In vivo cross-linking of ExeA, ExeB and ExeC to peptidoglycan 
3.1.1 Cross-linking of ExeA to peptidoglycan 
The presence of a putative peptidoglycan binding domain (Pfam number PF01471, 
analyzed in more detail in section 3.6) at the C-terminus of ExeA suggests that this protein 
may functionally interact with peptidoglycan. This hypothesis was examined by in vivo 
cross-linking. Wild type A. hydrophila Ah65 cells were incubated with 0.5 mM cleavable 
cross-linker DTSSP for 0 to 10 min, followed by extraction of peptidoglycan with boiling 
SDS (Hancock and Poxton, 1988). The peptidoglycan samples, as well as the whole cell 
samples, were immunoblotted for the presence of ExeA (Fig. 9A). In the absence of reducing 
agent, the cross-linked whole cell samples showed that the ExeA monomer band was shifted 
into much higher molecular weight bands, which might include the ExeAB complex as 
demonstrated previously (Schoenhofen et al., 1998). In the presence of β-mercaptoethanol, 
the high molecular weight ExeA-containing bands disappeared and the monomer band 
appeared again in the immunoblot, confirming the cross-linking by DTSSP. The immunoblot 
also shows that ExeA was found in the peptidoglycan samples isolated from cross-linked 
cells in the presence of β-mercaptoethanol but not in its absence or in the non-cross-linked 
control. This suggests that ExeA was cross-linked to peptidoglycan by DTSSP. Because 
peptidoglycan cannot enter SDS-PAGE gels due to its large size, ExeA cross-linked to 
peptidoglycan remained out of the gel unless the cross-linker was broken by treatment with 
β-mercaptoethanol before electrophoresis. As a control, the major lipoprotein (Lpp), a 
known peptidoglycan associated protein, was also found to cross-link to peptidoglycan 
(Fig.9A). 
To control for the possibility that the cross-linking of ExeA with peptidoglycan was an 
artifactual linkage of nonassociated components, A. hydrophila cells expressing mutant 
ExeAs that contained substitution mutations in the putative peptidoglycan binding motif 
(pCG1: F487S, pCG2: L493S and pCG3: G500D) were also used in the cross-linking studies 
(Fig. 9B). In this experiment, the wild type ExeA was again present in the cross-linked 
peptidoglycan, however, the three mutants were present in much reduced quantities.
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Fig. 9 In vivo cross-linking of ExeA to peptidoglycan. A. Cross-linking of ExeA to 
peptidoglycan. A. hydrophila Ah65 cells were cross-linked with 0.5 mM DTSSP for 0 to 10 
min, followed by isolation of peptidoglycan by boiling SDS treatment. Whole cell and 
peptidoglycan samples were treated with or without β-mercaptoethanol before being applied 
to SDS-PAGE and immunoblotted with ExeA antiserum. The samples were also 
immunoblotted for the major lipoprotein (Lpp) at the bottom of the panel. B. Cross-linking 
of ExeA variants to peptidoglycan. A. hydrophila C5.84 cells expressing wild type (pRJ31.1) 
or putative peptidoglycan binding motif mutant ExeAs (pCG1, pCG2 and pCG3) were cross-
linked with 0.5 mM DTSSP for 5 min. Whole cell and peptidoglycan samples were treated 
with β-mercaptoethanol before electrophoresis and anti-ExeA immunoblot. 
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This demonstrates that the cross-linking of ExeA to peptidoglycan was specific and required 
the putative peptidoglycan binding domain. 
 
3.1.2 Co-crosslinking of ExeB and ExeC to peptidoglycan 
ExeA and ExeB have been shown to cross-link into a heterodimeric complex in vivo 
(Schoenhofen et al., 1998). We therefore examined if ExeB was also present in the 
peptidoglycan samples isolated from cross-linked cells. The immunoblot shows that ExeB 
was detected in the peptidoglycan sample of wild type ExeA (pRJ31.1) but not in that of 
mutant ExeA (pCG3) (Fig. 10B). This result confirms the ExeAB complex reported 
previously (Schoenhofen et al., 1998). It also suggests that ExeB was co-crosslinked to 
peptidoglycan through ExeA, or alternatively, the cross-linking of ExeB to peptidoglycan 
required a functional ExeA. Similarly, ExeC was found co-crosslinked to peptidoglycan in 
the presence of wild type ExeA (pRJ31.1) but not in its absence (pCG1, pCG2 and pCG3) 
(Fig. 10A). These cross-linking studies suggest an ExeA-B-C complex associated with 
peptidoglycan. 
 
3.2 In vitro cosedimentation of pExeAs with peptidoglycan 
3.2.1 Construction and purification of pExeAs 
Since ExeA is an insoluble membrane protein, the C-terminal/periplasmic domain of 
ExeA (pExeA), from a.a. 296 to a.a. 547, was cloned with a His-tag at the N-terminal end 
(N-His pExeA) or at the C-terminal end (C-His pExeA). pExeAs with substitution mutations 
of three highly conserved amino acid residues at the putative peptidoglycan binding motif 
(N-His pCG1, N-His pCG2, N-His pCG3, C-His pCG1, C-His pCG2 and C-His pCG3) were 
also constructed. The linear maps of the pExeA variants are shown in Fig. 11. pexeA 
fragments were PCR amplified from pRJ31.1 or pCGs and inserted into the NdeI-XhoI sites 
of the pET30a vector. All constructs were sequenced to rule out the possibility of unwanted 
mutations before being electroporated into E. coli BL21 (DE3) cells for expression. The 
plasmid for C-His pExeA was constructed by Melody Harrington, a former summer student 
in Dr. Howard’s laboratory. 
Cells producing pExeAs were disrupted by French Press and the proteins were purified 
by His-tag affinity chromatography and ion exchange chromatography. All pExeA 
  
 
 
 
 
 
           
 
Fig. 10 Co-crosslinking of ExeB and ExeC to peptidoglycan. A. hydrophila C5.84 strains 
expressing wild type ExeA (pRJ31.1) and mutant ExeAs (pCG1, pCG2 and pCG3) were 
cross-linked with 0.5 mM DTSSP before isolation of peptidoglycan by boiling SDS 
treatment. Whole cell and peptidoglycan samples were treated with β-mercaptoethanol 
before SDS-PAGE and immunoblotting with ExeC antiserum (A) and ExeB antiserum (B). 
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Fig. 11 Linear maps of ExeA and pExeA constructs. The cytoplasmic region, trans-
membrane region and periplasmic region of ExeA are drawn to scale with amino acid 
residue numbers indicated. The ATP binding/hydrolysis motifs Walker A, Walker B and 
kinase-3a are indicated in yellow. The hydrophobic trans-membrane region is marked in 
blue. The putative peptidoglycan binding domain is marked in pink. The three highly 
conserved amino acid residues subjected to mutagenesis are indicated, corresponding to 
pCG1 (F487S), pCG2 (L493S) and pCG3 (G500D), respectively. N- or C-His tagged pExeA 
constructs containing the C-terminal 296-547 residues of ExeA are also illustrated. 
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preparations were examined on SDS-PAGE for purity. Their theoretical extinction 
coefficients at 280 nm were obtained with ProtParam software and used to calculate protein 
concentrations. Purified N-His pExeA, C-His pExeA and N-His pCG3 are shown in Fig. 12. 
N-His pCG1, N-His pCG2, C-His pCG1 and C-His pCG2 were found to be unstable and 
fractionated as multiple peaks in ion exchange chromatography (data not shown). It is likely 
that the two mutations F487S and L493S interfered with the normal folding of this protein 
(see more details in section 3.6.2). They were therefore not used in the following binding 
studies. 
 
3.2.2 Non-denaturing and denaturing purification of peptidoglycan 
The routine method to purify peptidoglycan involves extensive treatment in boiling 
SDS solutions (Glauner 1988; Hancock and Poxton, 1988). The initial in vitro 
cosedimentation studies of pExeA and SDS-purified peptidoglycan failed to show 
convincing interactions between them (data not shown). To address the possibility that the 
interactions required peptidoglycan-associated proteins, non-denatured peptidoglycan was 
isolated and used in cosedimentation studies to compare with denatured peptidoglycan for 
ability to interact with pExeA. ExeAB mutant stain A. hydrophila C5.84 was used to purify 
peptidoglycan samples to avoid possible interference caused by native ExeA. 
Non-denatured peptidoglycan was prepared by washing cell envelopes with cold 2% 
Triton X-100 solutions containing 20 mM MgCl2 and 5 mM EDTA, separately, to remove 
membrane lipids (Schoenhofen et al., 1998). Theoretically, covalently bound proteins, such 
as the major lipoprotein, and tightly non-covalently bound proteins should remain in the 
peptidoglycan sample. Denatured peptidoglycan was prepared by extensive washing in 
boiling 4% SDS and treatment with pronase to remove all proteins linked to peptidoglycan, 
as described by Glauner, 1988. Aliquots of Triton X-100-treated, SDS-treated and 
SDS/pronase-treated peptidoglycan preparations were hydrolyzed overnight with lysozyme 
before analysis on SDS-PAGE, because proteins linked to peptidoglycan could not to enter 
the gel. As shown in Fig. 13, the Triton X-100-treated peptidoglycan sample contained many 
protein contaminants; in contrast, little or no protein contamination was found in the SDS-
treated and SDS/pronase-treated samples. 
To quantitate peptidoglycan samples, a colorimetric method was used to measure the
  
 
 
 
 
 
    
 
Fig. 12 Coomassie Brilliant Blue stained SDS-PAGE gel of purified pExeAs. His-tagged 
pExeA proteins N-His pExeA, C-His pExeA and N-His pCG3 were purified by His-tag 
affinity chromatography and ion exchange chromatography. The samples were applied to a 
SDS-PAGE gel and stained with Coomassie Brilliant Blue R250. 
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Fig. 13 Coomassie Brilliant Blue stained SDS-PAGE gel of non-denatured and 
denatured peptidoglycan preparations. Non-denatured peptidoglycan sample was isolated 
from A. hydrophila C5.84 cells by treatments with 2% Triton X-100 solutions containing 20 
mM MgCl2 and 5 mM EDTA, separately. Denatured peptidoglycan samples were isolated by 
boiling 4% SDS treatment and pronase digestion treatment (Glauner 1988). The samples 
were hydrolyzed with lysozyme before SDS-PAGE. The gel was stained with Coomassie 
Brilliant Blue R250. 
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lactic acid released from the muramic acid residues of peptidoglycan upon acidic and 
alkaline treatments (Hadzija, 1974; Hoijer et al., 1995). A blue colour is developed when 
copper is reduced by the lactic acid in the presence of 4-phenylphenol in concentrated 
H2SO4. The yield of A. hydrophila peptidoglycan was about 2 millimole muramic acid units 
per litre per OD of cell culture, or 2 mg L-1·OD-1 if the average muropeptide molecular 
weight is 1 kDa, comparable to the yield of 2.08 mg L-1·OD-1 from E. coli reported by 
Glauner (1988). 
In addition, peptidoglycan samples were also purified from E, coli and the Gram-
positive Bacillus subtilis with boiling SDS treatment for in vitro pExeA-peptidoglycan 
studies. The yield of B. subtilis peptidoglycan was about 25 mg L-1·OD-1. 
 
3.2.3 Cosedimentation of pExeAs with non-denatured peptidoglycan 
Peptidoglycan purified with boiling SDS treatment was first used in cosedimentation 
studies with pExeAs. In 40 mM sodium phosphate (pH 6.5), wild type N-His pExeA and 
mutant N-His pCG3 were both able to cosediment with the denatured peptidoglycan 
preparation, detected by SDS-PAGE and Coomassie Brilliant Blue stain (data not shown). 
However, when 0.05% Tween 20 was added, no cosedimentation could be observed with 
either protein (data not shown), suggesting non-specific interactions in the cosedimentation 
experiments. It is possible that the pExeA-peptidoglycan interactions were too weak to 
detect by Coomassie Brilliant Blue stain. It is also possible that the interactions required 
peptidoglycan-associated proteins which were denatured during SDS treatment. To examine 
these possibilities, non-denatured peptidoglycan and more sensitive immunoblot were used 
in the following cosedimentation studies. 
Wild type (N-His pExeA) and mutant (N-His pCG3) pExeA proteins (10 nM) were 
incubated with 100 µM muramic acid units of non-denatured A. hydrophila peptidoglycan in 
40 mM sodium phosphate containing 0.05% Tween 20 at 4 °C for one hour, followed by 
centrifugation to recover peptidoglycan. The mixture, supernatant and pellet samples were 
examined by immunoblot with ExeA antiserum. Fig. 14 shows that N-His pExeA was found 
in the pellet sample; however, N-His pCG3 cosedimented to a much lower degree, 
suggesting specific cosedimentation and involvement of the putative peptidoglycan binding 
domain in these interactions. 
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Fig. 14 Cosedimentation of pExeAs with non-denatured peptidoglycan. 10 nM N-His 
ExeA (wild type) and N-His pCG3 (mutant) were mixed with 100 μM muramic acid units of 
A. hydrophila peptidoglycan, purified by Triton X-100 treatments, in 40 mM sodium 
phosphate (pH6.5) and 0.05% Tween 20 at 4 °C for one hour, followed by centrifugation to 
pellet the peptidoglycan. The mixture, supernatant and pellet samples were applied to SDS-
PAGE and immunoblotted with ExeA antiserum. The pellet samples were 30 times 
concentrated during resuspension. 
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3.2.4 Cosedimentation of pExeAs with denatured peptidoglycan 
To examine if proteins, lipids or other impurities included in the non-denatured 
peptidoglycan sample were actually involved in the interactions with pExeA, peptidoglycan 
samples prepared with treatments known to denature or degrade proteins, such as boiling 
SDS and pronase hydrolysis (Glauner, 1988), were used in the cosedimentation assays. The 
effects of these treatments were confirmed in Fig. 13 (page 45) as little or no proteins were 
found in these samples. The result of cosedimentation with the pure peptidoglycan sample is 
shown in Fig. 15. Once again, N-His pExeA, but not the mutant N-His pCG3, was present in 
the pellet sample of Triton X-100 treated A. hydrophila peptidoglycan. A similar amount of 
N-His pExeA was also found in the pellet sample of SDS/pronase treated peptidoglycan; 
however, the mutant protein bound much less. This indicates that pExeA interacted with the 
peptidoglycan backbone but not with proteins or lipids associated with peptidoglycan. It was 
noticed that the mutant pExeA cosedimented much more with the pure peptidoglycan, 
possibly because of elimination of impurities that prevent weak interactions. SDS/pronase 
treatment was therefore used in all peptidoglycan purifications in the following studies. 
These results imply that the ExeA-binding component of peptidoglycan accounts for 
only a small part of the peptidoglycan, because a 10,000 fold excess of muramic acid units 
of peptidoglycan are required to bind the small amount of pExeA detected on the 
immunoblot. This could also be caused by very low affinity pExeA-peptidoglycan 
interactions. Our trials for affinity analysis did not yield a satisfactory binding curve. This 
was partially due to the limitations of the cosedimentation assay, in which the peptidoglycan 
forms large pellets that could non-specifically trap proteins, because of its rigid net-like 
structure. It may also have been caused by the complicated nature of the pExeA-
peptidoglycan interactions, which have been shown to be accompanied by multimerization 
of the protein (see section 3.5). 
To examine if pExeA interacts with a universal peptidoglycan structure, peptidoglycan 
samples extracted from E. coli and the Gram-positive B. subtilis were also used in 
cosedimentation assays. Fig. 15 shows that similar results for N-His pExeA and N-His pCG3 
were obtained with the E. coli peptidoglycan preparation. However, the B. subtilis sample 
failed to cosediment the protein (data not shown). Further analysis indicated that N-His 
pExeA could interact with B. subtilis peptidoglycan after it had been hydrolyzed by
  
 
 
 
 
 
 
     
 
Fig. 15 Cosedimentation of pExeAs with different peptidoglycan preparations. 
Peptidoglycan samples were prepared by Triton X-100 treatment or SDS/pronase treatment 
from A. hydrophila or E. coli cells as indicated. The cosedimentation was performed as 
described previously, except that only pellet samples were analyzed by SDS-PAGE and 
ExeA immunoblot. 
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mutanolysin into small fragments (see later in sections 3.4 and 3.5). A possible explanation 
could be that the multi-layer structure of B. subtilis peptidoglycan prevented access of the 
protein to the binding sites or its multimerization. These results suggest that pExeA could 
interact with a peptidoglycan structure conserved in different bacteria, consistent with the 
widespread occurrence of the putative peptidoglycan binding domain in a variety of species. 
C-His tagged pExeA was also examined for its ability to interact with peptidoglycan 
(Fig. 16). Surprisingly, the addition of the tag to the C-terminal side of the protein almost 
completely abrogated cosedimentation, so that it bound much less than even the mutant N-
His pCG3. This may be because the putative peptidoglycan binding domain (a.a. 441–507) is 
located near the C-terminal end of pExeA (a.a. 296–547). The C-His tag might hinder 
peptidoglycan from accessing its binding site on pExeA, or alternatively, affect the normal 
folding and 3-D structure of this domain. In the following studies, C-His pExeA was 
therefore used as a negative control that had lost its ability to interact with peptidoglycan. 
 
3.2.5 Cosedimentation at various pHs and salt concentrations 
Cosedimentation of pExeA and peptidoglycan was examined in buffers of different pHs 
and salt concentrations. Fig. 17 shows that the cosedimentation was pH-dependent. At pH 
7.4 or above, very little N-His pExeA cosedimented with peptidoglycan, whereas at pH 6.0, 
the cosedimentation was highest. These results were not due to precipitation of the protein at 
lower pH, as indicated by non-peptidoglycan controls (data not shown). The theoretical pI of 
pExeA is 4.8. At lower pHs, the protein should be less negatively charged. The charges may 
possibly affect pExeA-peptidoglycan interactions or pExeA-pExeA interactions. The latter 
will be analyzed in more detail in sections 3.3 and 3.5. The periplasmic environment is 
slightly acidic, as protons diffuse into the periplasm from outside of the cell due to a Donnan 
equilibrium that causes uneven distribution of charges across the outer membrane (negative 
inside), resulting in a pH of around 6.5 (Dhungana et al., 2003). In addition, bacteria are 
known to release protons into the periplasm to establish protonmotive force as an energy 
source (Mitchell, 1966). The pH requirement observed for pExeA-peptidoglycan interactions 
is therefore consistent with the physiological environment. 
The cosedimentation was also affected by salt concentration (Fig. 18). N-His pExeA 
showed decreased cosedimentation at 50 mM NaCl and above. It should be noted that the
  
 
 
 
 
 
 
 
 
  
 
Fig. 16 Cosedimentation analysis of N- and C-His tagged pExeAs. N-His pExeA, N-His 
pCG3 and C-His pExeA (0.5 to 4 nM) were incubated with 100 μM muramic acid units of A. 
hydrophila peptidoglycan in the cosedimentation assay as described previously, except that 
only pellet samples were analyzed on SDS-PAGE and immunoblotted with ExeA antiserum. 
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Fig. 17 Cosedimentation of pExeA with peptidoglycan at various pHs. N-His pExeA (10 
nM) was incubated with 100 μM muramic acid units of A. hydrophila peptidoglycan in 40 
mM sodium phosphate of pH 6.0, 6.5, 7.4 and 8.0 with 0.05% Tween 20. After 
centrifugation, the pellets were resuspended in a same volume of buffer. The mixture, 
supernatant and pellet samples were applied to SDS-PAGE and immunoblotted with ExeA 
antiserum. 
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Fig. 18 Cosedimentation of pExeA with peptidoglycan at various salt concentrations. 
N-His pExeA (10 nM) was incubated with 100 μM muramic acid units of A. hydrophila 
peptidoglycan in 40 mM sodium phosphate of pH 6.0 and 6.5 with 0.05% Tween 20 and 0 to 
150 mM NaCl. The pellets samples were five times concentrated during resuspension. The 
mixture, supernatant and pellet samples were applied to SDS-PAGE and immunoblotted 
with ExeA antiserum. 
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buffers used in these assays contained 40 mM sodium phosphate, weakening the possibility 
that the cosedimentation was caused by non-specific interactions. 
 
3.3 Multimerization of pExeA at elevated temperatures 
3.3.1 Analysis of pExeA multimerization by DLS 
Multimerization of pExeA was first observed when the protein was examined with 
Dynamic Light Scattering (DLS) for crystallization purpose. DLS analyzes scattered light 
intensity fluctuation to derive the hydrodynamic radius (RH) of molecules. RH is then used to 
calculate molecular mass (Murphy, 1997). N-His pExeA samples in 40 mM sodium 
phosphate buffers of pH 6.5 and 8.0, 150 mM NaCl were measured at the range of 
temperatures from 4 ºC to 37 ºC with 5 min incubation at each temperature point. The result 
of temperature scanning is shown in Fig. 19. At 4 °C, the 29 kDa N-His pExeA showed an 
average RH of 3 nm or an apparent molecular weight of 58.4 kDa, suggesting that dimers 
were prevalent under this condition. However, the RH was increased when the temperature 
was raised above 25 °C. An RH of 6-7 nm was observed at 37 °C, indicating that large 
multimers were formed. The multimerization of this protein was favoured by low pH, as 
shown by delayed multimerization at pH 8.0 compared to pH 6.5. Because pExeA has a pI of 
4.8, the protein was less negatively charged at lower pH, possibly resulting in increased 
accessibility for multimerization. 
The particle size distribution of N-His pExeA was analyzed using DynaLS software, 
shown in Fig. 20.  At 4 ºC, the protein showed a single peak at RH 3 nm. After the sample 
was incubated at 37 ºC for one hour followed by storage at 4 ºC overnight, the protein 
showed a second peak at 10 nm, suggesting formation of large multimers. Since RH is highly 
dependent on particle shape, accurate molecular weights of the multimers were difficult to 
derive by this method. 
 
3.3.2 Analysis of pExeA multimerization by gel filtration 
To confirm that the multimerization of N-His pExeA observed in DLS was not caused 
by non-specific aggregation at elevated temperature, the protein was also examined by gel 
filtration. 2 mg/ml N-His pExeA was applied to a Superdex 200 10/300 GL column (GE 
Healthcare) in 40 mM sodium phosphate (pH 6.5) and 150 mM NaCl at 4 ºC (Fig. 21).
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 Multimerization of pExeA at elevated temperatures by DLS. 2 mg/ml N-His 
pExeA were measured for average hydrodynamic radius (RH) in 40 mM sodium phosphate 
of pH 6.5 or 8.0, 150 mM NaCl at the range of temperatures from 4 °C to 37 °C by DLS. 
The samples were incubated at each temperature for 5 min before average RH was measured. 
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Fig. 20 Size distribution of pExeA by DLS. 2 mg/ml N-His pExeA in 40 mM sodium 
phosphate (pH 6.5) and 150 mM NaCl was incubated at 37 ºC for one hour followed by 
sitting at 4 ºC overnight. The incubated sample and a sample without incubation were 
measured at 4 ºC by DLS. The particle size distribution for hydrodynamic radius (RH) was 
analyzed using DynaLS software. 
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Fig. 21 Size distribution of pExeA by gel filtration. A. Gel filtration of pExeA. 2 mg/ml 
N-His pExeA with or without incubation at 37 ºC for one hour were applied to a Superdex 
200 10/300 GL column (GE Healthcare) in 40 mM sodium phosphate (pH 6.5) and 150 mM 
NaCl. The gel filtration was performed at 4 ºC with a flow rate of 0.5 ml/min. Protein 
markers (Sigma) were also applied in a parallel experiment. Their elution positions are 
indicated at the top of the graph. B. Size determination of pExeA. The molecular weight vs. 
the Ve/Vo (elution volume/void volume) for each protein marker is plotted using a semi-
logarithmic scale. The Ve/Vo values for the pExeA peaks (▼ and   ) are plotted and their 
apparent molecular weights indicated, accordingly. 2000 kDa (void volume): blue dextran; 
200 kDa: β-amylase (sweet potato); 150 kDa: alcohol dehydrogenase (yeast); 29 kDa: 
carbonic anhydrase (bovine erythrocytes); 12.4 kDa: cytochrome c (horse heart). 
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Without incubation at 37 ºC, the protein eluted as closely spaced, double peaks. By 
comparison with protein standards, the two peaks correspond to pExeA dimers and 
monomers. After the protein was incubated at 37 ºC for one hour, the dimer peak 
disappeared and a new peak with an apparent molecular weight of 600 kDa appeared. This 
peak eluted 2 ml after a small peak at the void volume of 8.4 ml. It was thus not likely 
caused by protein precipitation. 
 
3.3.3 Analysis of pExeA multimerization by native gradient PAGE 
Native gradient PAGE was used to further analyze the pExeA multimers induced at 
elevated temperatures. The method was modified from the blue native PAGE reported by 
Schagger (2001), in which Coomassie Brilliant Blue G-250 is added in the cathode buffer to 
give the proteins negative charge for electrophoresis. In the initial trials, N-His pExeA 
multimers ran as smears with the blue dye in the cathode buffer (data not shown). The 
electrophoresis was improved in the absence of the blue dye as shown in Fig. 22. N-His 
pExeA has a pI of 4.8 and therefore under the running conditions (pH 7.0), does not need to 
bind the dye to become negatively charged. N-His pExeA (2 mg/ml) was incubated at 37 ºC 
for one hour and then 4 ºC for one hour before being electrophoresed at 4 ºC. The presence 
of distinctive multiple pExeA bands in the native PAGE gel suggests that the components of 
the multimers had confined structures, and thus that the multimers were not likely to be 
caused by denaturation and aggregation. To examine the stability of the pExeA multimers, 
one sample was stored at 4 ºC overnight before being loaded on the gel. It showed that the 
amount of multimer in the sample was decreased by approximately half, suggesting that the 
multimerization is at least partially reversible. 
 
3.4 Separation and identification of peptidoglycan fragments interacting with pExeA 
3.4.1 Cosedimentation inhibition analysis of peptidoglycan fragments 
Since peptidoglycan is a cell-sized structure (the sacculus), hydrolysis of peptidoglycan 
into small fragments was required to further characterize the pExeA-peptidoglycan 
interactions. A. hydrophila peptidoglycan was incubated at 37 ºC overnight with mutanolysin 
(Sigma), an N-acetylmuramidase that cleaves peptidoglycan at the β-1,4 glycosidic bonds 
into muropeptides. The sample was centrifuged to remove unhydrolyzed peptidoglycan. The
  
 
 
 
 
 
 
 
 
 
Fig. 22 Native gradient PAGE of pExeA multimers. 2 mg/ml N-His pExeA samples were 
incubated at 37 ºC for one hour, followed by incubation at 4 ºC for one hour or overnight* 
before electrophoresis at 4 ºC in a native three-stage gradient PAGE gel. A sample without 
incubation at 37 ºC was also included (4 ºC). The proteins were visualized by Coomassie 
Brilliant Blue stain as for SDS-PAGE gels. 
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peptidoglycan fragments were examined for their ability to interact with pExeA by 
cosedimentation inhibition assays. N-His ExeA was first incubated with the peptidoglycan 
fragments before intact peptidoglycan was added. Any interactions of the fragments with N-
His pExeA would compete with the protein for binding and cosedimentation with the intact 
peptidoglycan. To further investigate the interactions, a commercial preparation of 
muropeptide, N-acetyl-D-glucosaminyl-(β1,4)-N-acetylmuramyl-L-alanyl-D-isoglutamine 
(Calbiochem), which contains only the first two amino acids of the peptide side chain, was 
also assayed. Fig. 23 shows that the peptidoglycan fragments, added at 4 times the muramic 
acid concentration of peptidoglycan in the assay, could inhibit the cosedimentation; whereas 
the commercial muropeptide, added at 16 times the muramic acid concentration of the 
peptidoglycan, could not. These data suggest that the peptidoglycan fragments were still able 
to interact with pExeA; however, muropeptides with longer peptides, larger structures, or 
special modifications are required for the interactions. 
 
3.4.2 Separation of peptidoglycan fragments by gel filtration 
The huge mass of peptidoglycan required cleavage by mutanolysin into small 
fragments, followed by gel filtration, to separate and identify the fragments that interacted 
with pExeA. However, the low yield of A. hydrophila peptidoglycan and the sensitivity limit 
of the muramic acid assay hindered this process in the initial trials. Peptidoglycan from the 
Gram-positive B. subtilis was therefore purified and used as an alternative for the following 
reasons. Firstly, the yield of peptidoglycan from B. subtilis was more than 10 times that from 
A. hydrophila (25mg L-1·OD-1 vs. 2mg L-1·OD-1). Secondly, the components of the 
peptidoglycan of Bacillus species have been extensively studied by HPLC and MS, which 
may assist in the identification of ExeA-binding fragments (Bacher et al., 2001). 
B. subtilis peptidoglycan was prepared by boiling SDS, pronase and concentrated 
hydrofluoric acid treatment to remove all proteins, lipids and anionic polymers attached to 
the peptidoglycan (Bacher et al., 2001), plus an additional treatment with DNase and RNase 
to reduce nucleic acid contamination (Antignac et al., 2003). The purified peptidoglycan
  
 
 
 
 
 
 
 
 
                              
 
Fig. 23 Cosedimentation inhibition assay of peptidoglycan fragments. N-His pExeA (0.8 
nM) was incubated with buffer or 200 μM muramic acid units of mutanolysin hydrolyzed A. 
hydrophila peptidoglycan fragments or 0.8 mM commercial muropeptide* (Calbiochem) at 
4 ºC for one hour before 50 μM muramic acid units of intact peptidoglycan were added. 
After centrifugation, the pellet samples were 30 times concentrated during resuspension. The 
samples were applied to SDS-PAGE and immunoblotted with ExeA antiserum. 
*: N-acetyl-D-glucosaminyl-(β1,4)-N-acetylmuramyl-L-alanyl-D-isoglutamine 
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sample was hydrolyzed overnight by mutanolysin at 37 ºC overnight, followed by 
inactivation of the enzyme at 95 ºC, and centrifuged to separate the supernatant that 
contained the peptidoglycan fragments. The supernatant was able to inhibit N-His pExeA 
from cosedimentation with A. hydrophila peptidoglycan (Fig. 25), indicating that the pExeA-
binding components were present in the B. subtilis peptidoglycan fragments. 
The B. subtilis peptidoglycan fragments were applied to a Superose 6 10/300 GL 
column for gel filtration. The fractions 15-48 (0.5 ml fraction size) were assayed for 
muramic acid concentration as shown in Fig. 24. A single muramic acid peak occurred in 
fraction 43 or an elution volume of 21.25 ml, after a 12.4 kDa protein marker eluting at a 
volume of 20.1 ml, suggesting that the peptidoglycan was almost completely hydrolysed into 
small fragments. 
 
3.4.3 Identification of peptidoglycan fractions interacting with pExeA 
The peptidoglycan gel filtration fractions were examined for their ability to interact with 
pExeA by cosedimentation inhibition assays. N-His pExeA was first incubated with 
peptidoglycan fragments at 4 ºC for one hour before intact A. hydrophila peptidoglycan was 
added. After centrifugation, the pellet samples were analyzed by anti-ExeA immunoblot, 
shown in Fig. 25. Fractions 36-42, but not the muramic acid peak fractions 43-44 that 
contained most of the muropeptides, could inhibit the cosedimentation of N-His pExeA with 
intact peptidoglycan, suggesting that larger peptidoglycan fragments were involved in the 
interactions. 
 
3.5 Multimerization of pExeA in the presence of peptidoglycan 
3.5.1 Multimerization of pExeA in the presence of intact peptidoglycan 
The ability of pExeA to self-multimerize at elevated temperature and its interactions 
with peptidoglycan made it of interest to examine the multimerization status of the protein in 
the presence of peptidoglycan. N-His pExeA (42 nM) was incubated with 250 μM muramic 
acid units of A. hydrophila peptidoglycan at room temperature for one hour, followed by the 
addition of lysozyme to fragment the peptidoglycan. The sample was centrifuged to remove 
uncleaved peptidoglycan before being applied to a Superdex 200 10/300 GL column for gel 
filtration. The resulting fractions were analyzed by immunoblot with ExeA antibodies.
  
 
 
 
 
 
 
 
Fig. 24 Muramic acid distribution of mutanolysin-digested B. subtilis peptidoglycan gel 
filtration fractions. 1 ml of 7 mM muramic acid units of B. subtilis peptidoglycan were 
hydrolysed with 1,000 units of mutanolysin (Sigma) overnight at 37 ºC. After centrifugation, 
0.5 ml of the supernatant was applied to a Superose 6 10/300 GL column (GE Healthcare) in 
40 mM sodium phosphate (pH 6.5) at 4 ºC and collected into 0.5 ml fractions. Fractions 15-
48 were assayed for muramic acid concentration. Protein markers (Sigma) were also applied 
in a parallel experiment. 669 kDa: thyroglobulin (bovine); 440 kDa: apoferritin (horse 
spleen); 66 kDa: bovine serum albumin; 12.4 kDa: cytochrome c (horse heart). 
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Fig. 25 Cosedimentation inhibition assay of mutanolysin-digested B. subtilis 
peptidoglycan gel filtration fractions. The mutanolysin-digested B. subtilis peptidoglycan 
fractions (Fig. 24, page 64) were assayed for their ability to interact with pExeA by 
inhibition of this protein from cosedimentation with intact A. hydrophila peptidoglycan. N-
His pExeA (1 nM) was incubated with 100 μl peptidoglycan fractions 36-45 (total 150 μl) at 
4 ºC for one hour before adding 230 μM muramic acid units of intact A. hydrophila 
peptidoglycan. After centrifugation to precipitate the peptidoglycan, the pellet samples were 
applied to SDS-PAGE and immunoblotted with ExeA antiserum. 
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Fig. 26 shows that in the absence of peptidoglycan, the 29 kDa protein eluted in fractions 31-
33 (0.5 ml fraction size), or an elution volume of 16 ml, consistent with the previous gel 
filtration result (Fig. 21, page 57). In the presence of peptidoglycan, however, some of the 
protein also eluted in fractions 16 and 17, or the void volume of 8.4 ml. The column has a 
separation range of 10 to 600 kDa for globular proteins. The protein was thus apparently 
included in very large complexes, corresponding to multimers of above 600 kDa containing 
about 20 monomers of N-His pExeA, depending on the shape of the multimers. This 
indicated that N-His pExeA multimerized upon interactions with peptidoglycan. However, it 
is also possible that the large complexes were due to a small amount of large peptidoglycan 
fragments that were not hydrolyzed by the lysozyme. 
 
3.5.2 Cross-linking analysis of pExeA multimerization in the presence of peptidoglycan 
fragments  
In vitro cross-linking was used to examine the interactions between N-His pExeA and 
the mutanolysin-digested B. subtilis peptidoglycan fragments. If N-His pExeA interacted 
with the peptidoglycan fragments and consequently multimerized, the protein would be 
cross-linked in different patterns than the non-peptidoglycan control and offer a direct way 
to examine the interactions of the peptidoglycan fragments with N-His pExeA. N-His pExeA 
(80 nM) was incubated with peptidoglycan fraction 37, which showed interactions with the 
protein in the cosedimentation inhibition assay (Fig. 25, page 65), at 4 ºC for two hours and 
cross-linked with 0 to 5 mM DTSSP on ice for 30 min. A sample with no peptidoglycan and 
an N-His pExeA sample induced multimerization at 37 ºC were also cross-linked as controls. 
Fig. 27 shows that the protein was cross-linked into closely spaced double bands as well as 
larger bands in the presence of the peptidoglycan fragments, as was observed for the N-His 
pExeA multimers induced at 37 ºC, whereas the non-peptidoglycan control showed little or 
no cross-linking. The closely spaced double bands corresponded to dimers by comparison of 
their apparent molecular weights with the protein markers. This result suggests interactions 
between N-His pExeA and the fragments in the peptidoglycan digest fraction 37, confirming 
the cosedimentation inhibition result. It also shows that the protein was self-crosslinked, not 
to peptidoglycan fragments, indicating that the peptidoglycan fragments induced the protein 
to form dimers or multimers in a similar arrangement as that of the temperature-induced
  
 
 
 
 
 
 
 
    
 
Fig. 26 Multimerization of pExeA in the presence of intact peptidoglycan. N-His pExeA 
(42 nM) was incubated with 250 μM muramic units of A. hydrophila peptidoglycan at room 
temperature for one hour, followed by hydrolysis of the peptidoglycan with 50 μg/ml 
lysozyme at room temperature for four hours. After centrifugation to remove unhydrolyzed 
peptidoglycan, the sample was applied to a Superdex 200 10/300 GL column (GE 
Healthcare) for gel filtration at 4 ºC. The fractions (0.5 ml fraction size) were examined on 
SDS-PAGE and immunoblotted with ExeA antiserum. A control without peptidoglycan was 
also included in the experiment. The column had a separation range of 10 to 600 kDa and an 
exclusion limit of 1300 kDa for globular proteins. The positions of protein markers (Sigma) 
are indicated. 2000 kDa (void): blue dextran; 200 kDa: β-amylase (sweet potato); 150 kDa: 
alcohol dehydrogenase (yeast); 29 kDa: carbonic anhydrase (bovine erythrocytes). 
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Fig. 27 Cross-linking analysis of pExeA in the presence of peptidoglycan fragments. N-
His pExeA (80 nM) was incubated with B. subtilis mutanolysin-digested peptidoglycan gel 
filtration fraction 37 (Fig. 24, page 64) at 4 ºC for two hours and cross-linked with 0 to 5 
mM DTSSP on ice for 30 min. A sample with no peptidoglycan added and an N-His pExeA 
multimer sample induced at 37 ºC were also cross-linked as controls. After cross-linking, the 
samples were applied to SDS-PAGE and immunoblotted with ExeA antiserum. 
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multimers. However, the quantity of N-His pExeA units in the multimers was difficult to 
estimate because of the low efficiency in cross-linking of the multimeric complexes. 
 
3.5.3 Cross-linking analysis of the peptidoglycan gel filtration fractions 
Since the cross-linking confirmed the interactions between pExeA and the B. subtilis 
peptidoglycan fraction 37, the whole set of mutanolysin-digested peptidoglycan gel filtration 
fractions were examined for their ability to interact with N-His pExeA by cross-linking 
analysis. The fractions were incubated with N-His pExeA at 4 ºC for two hours, followed by 
cross-linking with 1.2 mM DTSSP on ice for 30 min. To avoid quenching of DTSSP by the 
high concentrations of muropeptides that contain primary amines, fractions 40-44 were 
diluted to normalize the muramic acid concentration to 0.1 mM, approximately equivalent to 
its concentration across the rest of the column. Fig. 28 shows that the protein was cross-
linked into the distinct double-band dimers in the presence of a wide range of peptidoglycan 
fractions 15-40, but not with fractions 41-44 which contained the muramic acid peak. The 
weak interactions with fractions 41-42 in the cosedimentation inhibition assays were not 
observed in the cross-linking assays, possibly because these samples were diluted for 
normalization of muramic acid concentration. As a control, the cross-linking was repeated 
with a mixture of fraction 36 and the diluted muramic acid peak fraction 43. The protein was 
cross-linked at the same level in the presence of the mixture as it was in the presence of 
fraction 36 alone, indicating that the lack of cross-linking with the muramic acid peak 
fractions was not because these fractions contained materials that inhibited the pExeA-
peptidoglycan interactions or the cross-linking (Fig. 28). These results confirmed that pExeA 
did not interact with small muropeptides but with larger peptidoglycan fragments or special 
peptidoglycan structures that were not susceptible to mutanolysin hydrolysis. 
 
3.5.4 Characterization of pExeA-interacting peptidoglycan fragments 
To investigate the identity of the large peptidoglycan fragments or special 
peptidoglycan structures that interacted with pExeA in the above assays, the B. subtilis 
peptidoglycan fraction 36, which showed interactions with pExeA, was treated with 0.1 N 
HCl at 100 ºC for 15 min, which is known to cleave the lipid moiety of muropeptide lipid 
intermediates and probably also causes other modifications (van Heijenoort, 2007), and used
  
 
 
 
 
 
 
               
 
 
Fig. 28 Cross-linking analysis of mutanolysin-digested B. subtilis peptidoglycan gel 
filtration fractions. N-His pExeA (60 nM) was incubated with the mutanolysin-digested B. 
subtilis peptidoglycan fractions 15-44 (Fig. 24, page 64) for 2 hours at 4 ºC, followed by 
cross-linking with 1.2 mM DTSSP on ice for 30 min. The samples were examined by SDS-
PAGE and anti-ExeA `immunoblot. Fractions 40-44 of the muramic acid peak were diluted 
to normalize the muramic acid concentration to 0.1 mM in order to prevent cross-linker 
quenching by muropeptides. The cross-linking was repeated with fraction 36 and the diluted 
fraction 43 as well as with a mixture containing both fraction 36 and the diluted fraction 43, 
as shown in the right panel. The locations of protein markers (Sigma) are also indicated at 
the top of the panel. 2000 kDa (void): blue dextran; 669 kDa: thyroglobulin (bovine); 440 
kDa: apoferritin (horse spleen); 66 kDa: bovine serum albumin; 12.4 kDa: cytochrome c 
(horse heart). 
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in cross-linking analysis as described previously. Again, pExeA showed much increased 
cross-linking in the presence of fraction 36. However, the cross-linking was at the non-
peptidoglycan control level when the fraction was treated with HCl (Fig. 29). This result 
suggests that certain modifying groups, which could be removed by HCl hydrolysis, were 
involved in the interactions with pExeA. The possible modifying groups will be discussed in 
detail in the discussion and future studies sections. 
 
3.5.5 Gel filtration analysis of pExeA multimerization in the presence of peptidoglycan 
fragments 
To better examine the multimerization of pExeA upon interactions with peptidoglycan, 
small peptidoglycan fragments were used in the following co-gel filtration studies. The 
mutanolysin-digested B. subtilis gel filtration fractions 38-40 (Fig. 24, page 64) were 
combined and incubated with N-His pExeA at 4 ºC for one hour, followed by gel filtration 
on a Superose 6 10/300 GL column. The resulting fractions were analyzed by immunoblot 
shown in Fig. 30. In the absence of peptidoglycan fragments, the 29 kDa N-His pExeA 
eluted with a peak in fraction 20 (1 ml fraction size) or an elution volume of 19.5 ml with an 
apparent molecular mass of only 18 kDa, possibly because of low protein concentration and 
weak interactions with the column matrix. Upon incubation with the peptidoglycan fractions 
38-40, however, the protein was fractionated into much higher molecular weight fractions, 
peaking in fraction 15 or an elution volume of 14.5 ml with an apparent molecular mass of 
about 400 kDa. This result confirmed the interactions between N-His pExeA and the 
peptidoglycan fractions 38-40 in the cosedimentation inhibition and cross-linking studies 
(Fig. 25 and 28, page 65, 70). More interestingly, the protein-peptidoglycan complex 
apparent molecular weight of 400 kDa was much higher than the apparent molecular mass 
combination of N-His pExeA (18 kDa) and the peptidoglycan fractions 38-40 (20 kDa), 
suggesting that the protein formed large multimers comparable to the multimers induced at 
elevated temperature (Fig. 30). 
 
3.5.6 Relationship between multimerization and interactions with peptidoglycan 
Since the multimerization of N-His pExeA at low temperature required the presence of
  
 
 
 
 
          
 
Fig. 29 Characterization of pExeA-interacting peptidoglycan fragments. The 
mutanolysin-digested B. subtilis peptidoglycan fraction 36 (Fig. 24, page 64) was 
hydrolyzed with 0.1 N HCl at 100 ºC for 15 min and neutralized with 0.1 N NaOH. The HCl 
treated and untreated samples as well as a non-peptidoglycan control were used in cross-
linking assays with 40 nM N-His pExeA as described previously. After cross-linking, the 
samples were applied to SDS-PAGE and immunoblotted with ExeA antiserum. 
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Fig. 30 Multimerization of pExeAs in the presence of mutanolysin-digested 
peptidoglycan fragments. N-His pExeA, N-His pCG3 and C-His pExeA (80 nM) were 
incubated with mutanolysin-digested B. subtilis peptidoglycan gel filtration fractions 38-40 
(200 μl of each, total 650 μl, Fig. 24, page 64) in 40 mM sodium phosphate with 0.05% 
Tween 20 at 4 ºC for one hour before being applied to a Superose 6 10/300 GL column (GE 
Healthcare) in the same buffer for gel filtration at 4 ºC. pExeAs incubated at 4 ºC or 37 ºC in 
the absence of peptidoglycan fractions were also used as controls. Fractions 11-22 (1 ml 
fraction size) were analyzed by ExeA immunoblot for protein distribution. The positions of 
protein markers (Sigma) are indicated at the top of the figure. 669 kDa: thyroglobulin 
(bovine); 440 kDa: apoferritin (horse spleen); 66 kDa: bovine serum albumin; 12.4 kDa: 
cytochrome c (horse heart). 
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peptidoglycan fragments, it is apparent that the interactions with peptidoglycan induced the 
protein to multimerize. Two pExeA variants, N-His pCG3 and C-His pExeA, which showed 
decreased interactions with peptidoglycan (Fig. 16, page 51), were examined for 
multimerization in the presence of peptidoglycan fragments by co-gel filtration. Fig. 30 
(page 73) shows that the mutant protein N-His pCG3 was still able to form multimers, 
however, they were smaller in size and the concentration was lower. Furthermore, C-His 
pExeA, which showed little binding in the cosedimentation assay, had almost no ability to 
form multimers. These data show that the multimerization was correlated to the interactions 
with peptidoglycan. In other words, the protein that showed the highest interactions with 
peptidoglycan also had the highest ability to form multimers (N-His pExeA); whereas those 
with less binding ability also displayed less ability to multimerize (N-His pCG3 and C-His 
pExeA). It is possible that the binding to peptidoglycan introduced conformational changes 
that favoured multimerization of the protein. The data also show that the two proteins, N-His 
pCG3 and C-His ExeA, had decreased ability to form multimers at 37 ºC, suggesting the 
involvement of the putative peptidoglycan binding domain in the temperature-induced 
multimerization. The data also imply that the interactions are complex and involve both 
binding and multimerization, which could not be distinguished in the cosedimentation and 
co-gel filtration assays. 
3.6 Computer analysis of the putative peptidoglycan binding domain 
3.6.1 Analysis of the putative peptidoglycan binding domain family 
A BLAST (Altschul et al., 1990) search with InterProScan (Zdobnov and Apweiler, 
2001) indicates that the C-terminal periplasmic region of ExeA contains a putative 
peptidoglycan binding domain (Pfam number PF01471), which is conserved in a variety of 
enzymes related to bacterial cell wall degradation (Ghuysen et al., 1994), for example, spore 
cortex-lytic enzyme SleB in Bacillus cereus and hydrolase metallo (Zn) DD-peptidase in 
Streptomyces albus G (Moriyama et al., 1996; Dideberg et al., 1982). However, no 
convincing evidence that this domain does bind to peptidoglycan has been reported. Up to 
present, 2310 proteins have been shown to contain this domain, including eight proteins with 
crystal structures available (Pfam database). Seven of the eight crystal structures are 
eukaryotic (gelatinase A; gelatinase B; Prommp-1; Prommp-2-Timp-2 complex; human Type 
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IV collagenase precursor; human collagenase 3 and fibroblast stromelysin-1); one is 
prokaryotic (hydrolase metallo (Zn) DD-peptidase). All of the seven eukaryotic proteins are 
matrix metalloproteinases (MMP), which degrade extracellular matrix (Seiki, 1999). They 
contain an N-terminal domain that structurally resembles the peptidoglycan binding domain, 
but do not likely have a peptidoglycan binding function. It is thus interesting to compare the 
sequences and structures of the eukaryotic and prokaryotic proteins to identify and 
distinguish between the amino acid residues that are required for the folding of the domain 
and those that are required for the peptidoglycan binding function. 
The putative peptidoglycan binding domain features a three α-helices structure, as 
illustrated by gelatinase A (PDB Protein data bank entry 1CK7) and hydrolase metallo (Zn) 
DD-peptidase (PDB entry 1LBU) (Fig. 31). The two structures are used as models for 
eukaryotic and prokaryotic, respectively, in this study. 
The putative peptidoglycan binding domain family contains 2310 members, with 239 of 
them designated as seed proteins (4 protein sequences were withdrawn) (Pfam database for 
PF01471). The 235 seed proteins include 52 eukaryotic proteins and 183 prokaryotic 
proteins (1 archaea, 6 phages and 176 bacteria). The two groups of sequences were aligned 
separately by ClustalW2 (Larkin et al., 2007) and viewed by Jalview (Clamp et al. 2004), as 
shown in Fig. 32. Both of the two groups show two conserved peptide regions linked by a 
non-conserved region of variable length. The consensus sequences of the two groups were 
also aligned for comparison of conserved amino acid residues (Fig. 33). In the figures, 
“conservation” measures the conservation of physicochemical properties of amino acid 
residues. “Consensus” gives the most frequent residues and their percentage shown by the 
height of the bars. “Quality” indicates the alignment quality based on BLOSUM62 score 
(Eddy, 2004) on observed substitutions. Although the prokaryotic group and eukaryotic 
group share some similarity in amino acid conservation profiles, they contain significant 
variations, suggesting their distinct functions. We propose that the common amino acid 
residues shared by both groups are involved in folding the three α-helical structure; the 
residues conserved only in one group might be more specific for their special functions, e.g. 
peptidoglycan binding in the prokaryotic group or extracellular matrix binding related 
function in the eukaryotic group. To identify the common residues and the specific residues, 
the following arbitrary standards were used. For common residues, the residues should have
 
 
Fig. 31 Crystal structures of gelatinase A and hydrolase metallo (Zn) DD-peptidase. 
Gelatinase A (PDB entry 1CK7) and hydrolase metallo (Zn) DD-peptidase (PDB entry 
1LBU) are used as model proteins for the eukaryotic structure and prokaryotic structure, 
respectively, in analysis of the putative peptidoglycan binding domain family (PF01471). 
The putative peptidoglycan binding domains, shown in pink, are comprised of three α- 
helices. A. Side view of 1CK7; B. Top view of 1CK7; C. Side view of 1LBU; D. Top view 
of 1LBU. 
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conservation indexes of 3 and above and should be conserved in both groups. For 
peptidoglycan-specific residues, the residues should have conservation indexes of 3 and 
above in the prokaryotic group and should not be conserved in the eukaryotic group. The 
eukaryotic-specific residues were not analyzed in this study. The resulting residues are 
indicated in Fig. 33 (page 78), including 11 common residues and 11 peptidoglycan-specific 
residues. When these residues were marked on the 1LBU crystal structure, most of the 
common residues were buried in the structure, consistent with the hypothesis that they are 
required for folding; whereas the peptidoglycan-specific residues were located both on the 
surface and buried (data not shown). In addition, the peptidoglycan-specific residues did not 
strongly cluster. The peptidoglycan binding site was therefore not immediately evident using 
the analysis. It should be again noted that the nature of the interactions between the family 
members and peptidoglycan is unknown. Assigning a protein to this family is thus based 
solely on sequence similarity rather than on experimental evidence. This would include 
proteins that have similar structure but distinctive functions, e.g. the eukaryotic proteins, or 
non-functional proteins that contain mutations for important residues. The criteria for 
choosing peptidoglycan-specific residues were thus modified, including strengthening the 
weight of known peptidoglycan-binding proteins (1LBU and ExeA) in the alignment for 
conserved residues as described in more detail in the following section. 
 
3.6.2 Mapping and analysis of the putative peptidoglycan binding site 
Streptomyces albus G hydrolase metallo (Zn) DD-peptidase (PDB entry 1LBU) is the 
only prokaryotic member of the putative peptidoglycan binding family for which the crystal 
structure has been solved. The enzyme is able to cleave the D-Ala-D-Ala peptide bond of 
muropeptide. The crystal structure shows that the protein is comprised of an N-terminal 
putative peptidoglycan binding domain (a.a. 1-90) and a C-terminal Zn-containing catalytic 
domain (a.a. 91-213) (Dideberg et al., 1982; Ghuysen et al., 1994), as shown in Fig. 31 
(page 76). 
The sequence of 1LBU was aligned with the consensus sequence of the prokaryotic 
group as well as ExeA (Fig. 34). The 11 common residues conserved in both the prokaryotic 
group and eukaryotic group are also conserved in 1LBU and ExeA. However, only 2 of the 
11 putative peptidoglycan-specific residues are conserved in all of the three sequences,
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suggesting that they are not essential for the peptidoglycan binding function. The alignment 
shows that the three sequences share 12 identical residues and 7 conserved residues. When 
the 19 residues were marked on the 1LBU structure, half of them were clustered at one 
location on the surface, including K47, Q51, D62, I64, Q54, G66, T69, L59 and G58 (Fig. 
35). The site contains two hydrophobic residues (I64 and L59), one basic residue (K47) and 
one acidic residue (D62), as illustrated in Fig 35DE. We propose that this site is involved in 
the specific interactions with peptidoglycan. How these residues interact with peptidoglycan 
and what is the interacting ligand are not clear from the analysis. 
Substitution mutations of three highly conserved amino acid residues in the putative 
peptidoglycan binding site of ExeA (F487S, L493S and G500D) have been constructed prior 
to the structural analysis of this study. They abrogated the normal function of ExeA in 
secretion and its interactions with peptidoglycan (Howard et al., 2006; this study). The three 
amino acid residues correspond to F53, L59 and G66 of 1LBU, which are buried below the 
surface in the crystal structure. The three mutations may thus disrupt the normal folding of 
ExeA. Mutant ExeAs containing F487S and L493S did exhibit greatly reduced stability in 
vivo and in vitro (data not shown). To better understand the putative peptidoglycan binding 
site, four residues exposed on the surface have been chosen for mutagenesis analysis. They 
are K481, Q485, D496 and I498, corresponding to K47, Q51, D62 and I64 of 1LBU, 
respectively, as shown in Fig. 35F. Alicia Miller, a technician in Dr. Howard’s laboratory, is 
performing the mutagenesis experiments. The mutant ExeAs will be used in in vivo 
functional studies and in vitro binding studies to provide further understanding of the 
putative peptidoglycan binding site. Preliminary data have shown that this putative 
peptidoglycan binding site is required for the normal functions of ExeA in ExeD secretin 
assembly and secretion in vivo and in binding with peptidoglycan in vitro (unpublished 
results). 
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Fig. 35 Mapping and analysis of the putative peptidoglycan binding site. The 19 highly 
conserved residues in the prokaryotic consensus sequence, 1LBU and ExeA of the putative 
peptidoglycan binding domain family in Fig. 34 (page 80) are marked in yellow on the 
crystal structure of the putative peptidoglycan binding domain of 1LBU. K47, Q51, D62, I64, 
Q54, G66, T69, L59 and G58 cluster at one site on the surface and form the putative 
peptidoglycan binding site. A. Top view of the putative peptidoglycan binding domain. B. 
Front view. C. Back view. D. Top view for hydrophobicity distribution (hydrophobic 
residues in red and hydrophilic residues in blue). E. Top view for charge distribution on 
surface (oxygen in red and nitrogen in blue). F. Residues chosen for mutagenesis in ExeA 
(K47, Q51, D62 and I64). 
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4. DISCUSSION 
4.1 ExeA interacts with peptidoglycan 
ExeAB have been shown to form a complex in the inner membrane and function to 
locate and/or assemble the ExeD secretin into the outer membrane (Ast et al., 2002). Since 
a putative peptidoglycan binding domain is present in the periplasmic region of ExeA, it is 
proposed that the role of ExeAB is to generate gaps in peptidoglycan, a barrier in trans-
envelope assembly, to allow ExeD to traverse into the outer membrane (Howard et al., 
2006). In support of this hypothesis, disruption of this domain by mutagenesis abrogated 
the normal function of ExeA. The putative peptidoglycan binding domain (PF01471) is 
conserved in many peptidoglycan-associated proteins; however, no convincing evidence 
has been reported for interactions between the domain and peptidoglycan. It was therefore 
the objective of this thesis to examine ExeA-peptidoglycan interactions to provide further 
understanding for the function of the putative peptidoglycan binding domain and the role of 
ExeA in the T2SS of A. hydrophila. 
In this study, the interactions between ExeA and peptidoglycan were first shown by 
cross-linking in vivo. Wild type ExeA, but not the mutant proteins for the putative 
peptidoglycan binding domain, was found to cross-link to peptidoglycan, suggesting the 
involvement of the domain in ExeA-peptidoglycan interactions (Fig. 9, page 39). However, 
we could not exclude the possibility that the cross-linking was actually mediated through 
other proteins that formed an ExeA-containing complex with peptidoglycan. 
More convincing evidence of ExeA-peptidoglycan interactions was provided by the in 
vitro binding studies, in which the purified C-terminal periplasmic region of ExeA (pExeA) 
was able to cosediment with peptidoglycan preparations treated with boiling SDS and 
pronase (Fig. 15, page 49). This indicates that pExeA interacted directly with 
peptidoglycan, but not with proteins, lipids or other impurities attached to peptidoglycan. 
However, it must be noted that only a very small amount of pExeA cosedimented with 
peptidoglycan. In these assays, 100 µM or more muramic acid units of peptidoglycan could 
bind less than 10 nM pExeA (Fig. 14, 15, page 47, 49). The possibility that the 
cosedimentation was caused by non-specific interactions needs to be addressed. Strong 
evidence in support of specific interactions was provided by a mutant pExeA, which 
contained a substitution mutation in the putative peptidoglycan binding domain and showed 
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greatly reduced ability to cosediment with peptidoglycan (Fig. 16, page 51). Another 
pExeA construct, in which the His-tag was added at the C-terminal end of wild type 
pExeA, almost totally lost the ability to interact with peptidoglycan (Fig. 16, page 51). This 
may be explained on the basis that the putative peptidoglycan binding domain is located in 
the C-terminal half of pExeA; the closely attached C-His tag could therefore impair the 
normal structure of this domain or block the binding site for peptidoglycan access. In 
addition, 40 mM sodium phosphate, 0.05% Tween 20 and 10 µg/ml bovine albumin were 
used in the binding buffer to overcome weak and non-specific interactions. The low 
binding capacity might therefore indicate the low amount of ExeA-binding sites in the 
peptidoglycan preparations. Alternatively, high affinity may require the N-terminal domain 
of ExeA or ExeB, which were absent in these assays.  
The interactions between pExeA and peptidoglycan were also demonstrated in the 
cosedimentation inhibition, co-gel filtration and in vitro cross-linking assays (Fig. 23, 25, 
27, 28, 29, 30, page 62, 65, 68, 70, 72, 73). In these studies, pExeA was able to interact 
with peptidoglycan fragments, suggesting that intact peptidoglycan or large fragments are 
not required. 
The pExeA-peptidoglycan interactions were characterized in different buffer 
conditions. The cosedimentation was highest at pH 6.0 and almost abrogated at pH above 
7.4 (Fig. 17, page 52). The periplasm is slightly acidic (pH 6.5), because protons diffuse 
into the periplasmic space from the environment due to Donnan equilibrium across the 
outer membrane (Dhungana et al., 2003). In addition, bacteria release protons into the 
periplasm to establish protonmotive force (Mitchell, 1966). The observed pH requirement 
for the cosedimentation thus fits with the in vivo conditions. Ionic strength was also found 
to affect the pExeA-peptidoglycan interactions. Ionic concentrations above 120 mM (50 
mM NaCl plus 40 mM sodium phosphate, pH 6.5) greatly interfered with the 
cosedimentation (Fig. 18, page 53). The binding affinity of pExeA and peptidoglycan is not 
determined, since several trials with a series of different pExeA concentrations in 
cosedimentation assays failed to generate a saturable binding curve (data not shown). This 
may have been partially caused by the rigid net-like structure of peptidoglycan that could 
non-specifically trap proteins. It might also be caused by the complicated pExeA-
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peptidoglycan interactions, which have been shown to involve multimerization of the 
protein (discussed in the next section). 
During the preparation of this thesis, a report of physical interactions between 
peptidoglycan and the putative peptidoglycan binding domain was published (Briers et al., 
2007). The endolysins KZ181 and EL183 of P. aeruginosa bacteriophages ФKZ and EL 
both contain an N-terminal putative peptidoglycan binding domain and a C-terminal 
catalytic domain and are able to locally hydrolyze peptidoglycan to facilitate phage 
infection. In those studies, the two putative peptidoglycan binding domains were fused to 
green fluorescent protein (GFP), separately. Both of the fusion proteins were able to stain 
the cell surface of outer membrane-permeabilized P. aeruginosa homogeneously. It was 
also shown that the fusion proteins were able to stain P. aeruginosa peptidoglycan sacculi 
prepared with SDS treatment. The binding peaked at pH 8 and 8.5, much higher than the 
optimum pH (6.2 and 7.3) for the peptidoglycan lytic activities of the two proteins and the 
pH requirement (below 7.4) in our studies. Although the discrepancy could be caused by 
different characteristics of KZ181/EL183 and ExeA, other explanations should be 
addressed. Firstly, they did not use mild detergents to control non-specific interactions. In 
our studies, peptidoglycan samples exhibited a considerable hydrophobicity that could 
cause non-specific cosedimentation of both wild type and mutant pExeAs, ~1000 times 
more than that when 0.05% Tween 20 was added (data not shown). Secondly, a necessary 
control, mutant proteins that disrupted the putative peptidoglycan binding domain, was not 
included in the GFP fusion studies. Although a control of GFP without the putative 
peptidoglycan binding domain attached was used in their in vivo and in vitro experiments, 
the possibility of non-specific interactions caused by the domains was not excluded. 
The nature of ExeA-peptidoglycan interactions is not known. In peptidoglycan 
hydrolysis assays, the purified pExeA failed to decrease the turbidity of peptidoglycan 
suspensions of different bacteria (A. hydrophila, E. coli and Micrococcus) in all conditions 
tested (data not shown). The question is therefore raised: how does the protein generate 
gaps on peptidoglycan if it does not have hydrolytic activity? It should be noted that the full 
function of ExeA may require full length of ExeA or its associating protein ExeB. Besides 
direct hydrolysis, gaps could be achieved by disruption of the normal biosynthesis of 
peptidoglycan, for example, inhibition of peptidoglycan synthetic enzymes and activation 
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of peptidoglycan lytic enzymes. The peptidoglycan could also be locally modified by ExeA 
and thus exhibit abnormal susceptibility to these peptidoglycan-specific enzymes. In future 
studies, one direction could be to examine the possible interactions with ExeA and 
peptidoglycan-specific enzymes. 
Another interesting question is how ExeD finds the gaps and traverses through the 
peptidoglycan barrier, if ExeA does generate them. Connections are thus required to relate 
the ExeAB complex to the rest of the T2SS machinery. One connection was found between 
ExeAB and ExeC in the in vivo cross-linking studies. ExeB was co-crosslinked to 
peptidoglycan in the presence of wild type ExeA, but not in the presence of mutant ExeA 
for the putative peptidoglycan binding domain (Fig. 10B, page 41). This confirmed the 
ExeAB complex reported previously (Schoenhofen et al., 1998). More interestingly, ExeC 
was also co-crosslinked to peptidoglycan in the presence of ExeA (Fig. 10A, page 41). 
These data suggest a complex of ExeA-B-C that is associated with peptidoglycan through 
the putative peptidoglycan binding domain of ExeA. GspC has been reported to interact 
with GspD (Gérard-Vincent et al., 2002; Lee et al., 2004; Possot et al., 1999). In addition, 
direct ExeA-ExeD interactions were also demonstrated in other studies in Dr. Howard’s 
laboratory (unpublished data). These interactions may thus lead GspD to the assembly site 
created by GspAB. 
 
4.2 ExeA forms multimers on peptidoglycan 
Multimerization of pExeA at elevated temperature is intriguing. After purification, the 
protein was kept at 4 ºC for storage. At this temperature, the majority of the protein was in 
the form of monomers and dimers; however, the protein started to multimerize as the 
temperature was raised above 25 ºC, as shown in the DLS, gel filtration and native PAGE 
studies (Fig. 19, 20, 21, 22, page 55, 56, 57, 60). The multimers were not likely caused by 
denaturation and aggregation at high temperature, since they ran as distinctive bands in the 
native PAGE and thus had defined structures. The physiological significance of pExeA 
multimers was better addressed by the co-gel filtration and cross-linking experiments. After 
incubation with small peptidoglycan fragments at 4 ºC, the protein fractionated as large 
multimers of 400 kDa or higher (Fig. 30, page 73). Interactions with peptidoglycan were 
apparently required for the multimerization. Two pExeA constructs, N-His pCG3 and C-
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His pExeA, showed greatly reduced multimerization, corresponding to their reduced 
cosedimentation with peptidoglycan (Fig. 16, 30, page 51, 73). In vitro cross-linking 
showed that after incubation with peptidoglycan fragments, pExeA was cross-linked into 
distinctive closely spaced double bands similar to these of the temperature induced 
multimers, suggesting they shared a similar structure (Fig. 27, page 68). The binding with 
peptidoglycan perhaps introduced conformational changes of the protein or lowered the 
energy barrier for multimerization, which could be alternatively achieved by elevated 
temperature. 
The finding that pExeA formed multimers on peptidoglycan is novel but not 
surprising. Two components of the T2SS apparatus, GspE and GspD, have been shown to 
form a hexametric ring in the inner membrane platform and a 12-14 member multimeric 
ring in the outer membrane, respectively (Robien et al., 2003; Nouwen et al., 1999 and 
2000; Chami et al., 2005). In fact ring-like structures are prevalent in many trans-envelope 
machineries, for example, the type IV pilus, flagella and type III secretion systems (Craig 
and Li, 2008; Cornelis, 2006). In particular, the PulD secretin in K. oxytoca has been found 
to contain two rings. One protrudes in the periplasmic space, comprised of the N-terminal 
domain. One inserts in the outer membrane and forms the channel for secretion, comprised 
of the C-terminal domain (Chami et al., 2005). It was found that the N-terminal domain of 
ExeD was able to interact with pExeA in yeast two-hybrid assays (unpublished data in Dr. 
Howard’s laboratory). The predominant pExeA multimers were about 400 kDa (Fig. 30, 
page 73), calculated to contain 12-14 subunits of the 29 kDa protein, consistent with a 
secretin multimer containing 12-14 GspD subunits (Chami et al., 2005; Johnson et al., 
2006). 
It is possible that ExeA facilitates T2SS assembly by forming a multimeric ring on 
peptidoglycan. This may generate a gap large enough to accommodate the apparatus. 
Alternatively, the ExeA ring may act as a scaffold to direct the assembly of other 
components through ExeA-B, ExeA-C, ExeA-D and ExeC-D interactions. 
 
4.3 An unsolved puzzle: what special peptidoglycan structure does ExeA bind to? 
The identity of the peptidoglycan fragment interacting with pExeA or the putative 
peptidoglycan binding domain is not clear. It must be a common component conserved in 
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different bacteria, because pExeA was able to interact with peptidoglycan samples from A. 
hydrophila, B. subtilis, and E. coli (Fig. 15, 25, 27, 28, 29, 30, page 49, 65, 68, 70, 72, 73). 
This is also suggested by the wide distribution of the putative peptidoglycan binding 
domain among both Gram-positive and Gram-negative bacteria species (Pfam database). 
However, it also must be an unusual peptidoglycan structure. In cosedimentation assays, 
100 µM muramic acid units of peptidoglycan could only bind less than 10 nM pExeA (Fig. 
14, 15, page 47, 49). After B. subtilis peptidoglycan fragments were fractionated by gel 
filtration, the muramic acid peak fractions failed to interact with pExeA in cosedimentation 
inhibition and cross-linking assays (Fig. 25, 28, page 65, 70). Instead, the protein could 
interact with a wide range of fractions of apparent molecular weights from 20 kDa to over 
600 kDa with no detectable muramic acid contents. It is possible that large peptidoglycan 
pieces were required for the interactions; however, an incomplete digestion of 
peptidoglycan, which greatly moved the muramic acid peak towards high molecular weight 
fractions and thus contained more large peptidoglycan fragments, did not exhibit more 
interactions with pExeA in cross-linking analysis (data not shown). It is more likely that the 
large peptidoglycan fragments, which interacted with pExeA, contained special structures 
that were not susceptible to mutanolysin hydrolysis. The special structures may include 
chemical modifications, for example, N-deacetylation, O-acetylation and N-glycolylation, 
uncommon peptide length, for example, two and three amino acid residues, or unusual 
arrangement, for example, tri-muropeptides and tetra-muropeptides (Vollmer et al., 2008). 
The peptidoglycan binding domain may therefore not have a general peptidoglycan binding 
function, but a role in binding a special peptidoglycan structure during peptidoglycan 
biogenesis or at certain cell locations. 
Another possible reason for the large peptidoglycan fragments in gel filtration is that 
they are the artifactual result of hydrophobic aggregation. Although mature peptidoglycan 
is hydrophilic upon removal of hydrophobic lipoproteins, it is actually linked with a 
number of hydrophobic Lipid II moieties. Boiling SDS and pronase treatments are not able 
to cleave the undecaprenyl moiety. The hydrophobic moieties might clump to form 
particles of different sizes in gel filtration. It is therefore possible that pExeA-peptidoglycan 
interactions require the Lipid II intermediate. This could explain the apparently sparse 
nature of the pExeA-binding site in peptidoglycan preparations, since the Lipid II 
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intermediates only link to peptidoglycan during glycan synthesis. One possible effect of 
these interactions is interruption of normal peptidoglycan biogenesis and thus the creation 
of gaps in the peptidoglycan for T2SS apparatus assembly. This possibility was first 
examined by treatment of intact peptidoglycan with 0.1 N HCl at 100 ºC for 0 to 30 min to 
remove the lipid moiety (van Heijenoort, 2007). The sample showed at first increased and 
then decreased ability to cosediment pExeA (data not shown). This result is difficult to 
explain. It may be caused by removal of hydrophobic moieties and increased solubility 
allowing better interactions with pExeA. Or, perhaps the peptidoglycan sacculi were 
hydrolyzed to smaller pieces and this increased the accessibility of the protein to its binding 
sites. 
To resolve the above possibilities, the acidic treatment was repeated with the B. 
subtilis peptidoglycan gel filtration fraction 36. The treated sample lost the ability to cause 
pExeA multimerization in the cross-linking analysis (Fig. 29, page 72). This suggests that 
the undecaprenyl moiety was involved in the interactions with pExeA. However, we cannot 
exclude the possibility that the HCl treatment could also modify peptidoglycan by 
deacetylation or removal of other residues. It should be noted that the methods used to 
purify peptidoglycan in this thesis involved unbuffered SDS solutions and hydrofluoric acid 
(for B. subtilis peptidoglycan), which should release the O-acetyl groups (Vollmer 2008). If 
the O-acetyl groups were involved in the interactions and the methods for peptidoglycan 
purification caused partial deacetylation, they would explain the apparently sparse nature of 
the pExeA-binding sites. However, if the O-acetyl groups were fully hydrolyzed during 
peptidoglycan purification, it would exclude the possibility of involvement of the O-
acetylation in these interactions. In future studies, special care should be taken to preserve 
the labile O-acetyl groups in peptidoglycan purification, as described by Bera et al. (2005) 
or Weadge and Clarke (2007). 
Other efforts to identify the ExeA component that interacts with peptidoglycan 
included the computer analysis of the putative peptidoglycan binding domain. When the 
highly conserved amino acid residues were located in the putative peptidoglycan binding 
domain of the 1LBU crystal structure, many of them were clustered at one surface location, 
suggesting that this site is the putative binding site for peptidoglycan (Fig. 35, page 82). 
The folding of this site (three α-helices) is quite different than the peptidoglycan binding 
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sites in known crystal structures of transpeptidases (Macheboeuf et al., 2006), 
transglycosylases (Lovering et al., 2008), lytic transglycosylases (Scheurwater et al., 2008) 
and lysozymes (Strynadka and James, 1996). 
 
5. CONCLUSION 
The studies in this thesis provide evidence that demonstrates the interactions between 
ExeA and peptidoglycan both in vivo and in vitro. The interactions caused ExeA to 
multimerize, favouring a model in which ExeA and ExeB form a multimeric ring on 
peptidoglycan to generate a gap large enough to accommodate the type II apparatus and/or 
to act as a scaffold for assembly of the system (Fig. 36). It is unfortunate, however, that the 
peptidoglycan ligand for the putative peptidoglycan binding domain has not yet been 
identified. This difficulty perhaps reflects the nature of peptidoglycan, which is not simple 
or homogenous, but rather a complicated and heterogeneous structure. 
 
6. FUTURE STUDIES 
6.1 Identification of the peptidoglycan ligand 
The studies in this thesis have shown that pExeA binds to an unusual peptidoglycan 
structure that is not susceptible to mutanolysin hydrolysis. This fact poses a difficulty for 
the identification of the peptidoglycan ligand by HPLC and MS, which generally require 
uniform molecules. The finding that HCl treatment of peptidoglycan could remove 
modifying groups that are required for interactions with pExeA has implied a solution for 
this problem. 
The possible peptidoglycan modifications could be analyzed by HCl treatment of the 
peptidoglycan fractions that can interact with pExeA followed by HPLC and MS to analyze 
the hydrolysis products, particularly small molecules that may be released from 
peptidoglycan. In addition, peptidoglycan samples from different bacteria with known 
modifications, for example, N-deacetylation, muramic δ-lactam and O-acetylation as listed 
by Vollmer (2008), may be used in interaction studies with pExeA. O-Acetylated 
peptidoglycan preparation and analysis has been documented by Pfeffer et al. (2006). 
Alternatively, in vitro modifications of peptidoglycan, such as O-acetylation and N-
acetylation with acetic anhydride as described by Strating and Clarke (2001) and Briers et
  
 
 
 
 
  
 
 
       
Fig. 36 Model of the ExeAB ring on peptidoglycan. ExeAB forms a multimeric ring-like 
structure on peptidoglycan to generate a gap for assembly of the ExeD secretin. 
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al. (2007), might assist the identification. To examine the involvement of the undecaprenyl 
moiety in the interactions, Lipid II intermediate may be extracted using the method 
described by Higashi et al. (1967). 
 
6.2 In vitro assembly of T2SS subcomplex 
Our studies have suggested that ExeAB may create an assembly site and/or act as a 
scaffold for assembly of the rest of the T2SS components. In particular, ExeA was required 
for co-crosslinking of ExeC to peptidoglycan. ExeA-ExeD and ExeB-ExeD interactions 
have been shown in yeast two-hybrid assays (unpublished data in Dr. Howard’s 
laboratory). However, in vitro binding studies failed to show the ExeA-ExeD interactions. 
In these assays, pExeA or the N-terminal domain of ExeD was immobilized to a matrix via 
His-tag affinity or amine coupling. These techniques have two disadvantages, e.g. 
prevention of protein multimerization and requirement for pH higher than the physiological 
pH in the periplasm (His-tag), which have been shown to be important in pExeA-
peptidoglycan interaction in this thesis. 
In future studies, the interactions among other T2SS components could be analyzed 
using an in vitro cosedimentation system that includes peptidoglycan, pExeA and other Exe 
proteins. Since pExeA binds and cosediments with peptidoglycan, interactions between 
pExeA and other proteins may cause them to cosediment with the peptidoglycan as well. In 
such assays, immobilization of the proteins is not required, and this system may thus better 
mimic the in vivo environment of the periplasm, where ExeA multimer formation at the 
assembly site may be required to recruit other T2SS components. In addition, by presenting 
different Exe proteins in the assays, the order of T2SS assembly could also be investigated. 
The interactions could also be examined by in vitro cross-linking as described in this 
thesis, in which multimerization of pExeA has been demonstrated. By comparison of the 
cross-linked samples immunoblotted with different antibodies, we may be able to show 
hetero-complex and homo-multimerization in these interactions. 
 
6.3 Observation of pExeA ring-like structure 
In this thesis pExeA has been shown to form multimers upon interactions with 
peptidoglycan or at elevated temperature. It is thus proposed that the protein forms a ring-
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like structure. The possibility of ring-like structure formation could be examined by 
electron microscopy as described by Chami et al. (2005), in which the authors 
demonstrated that PulD, a homologue of ExeD in K. oxytoca, forms a 12-multimer ring 
structure. Alternatively, the multimers could be examined by atomic force microscopy 
(Andersen et al., 2009). 
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